# Patent

## Title
Synergistic fungicidal active substance combinations

## Abstract

Novel active compound combinations comprising a carboxamide of the general formula (I) (group 1)




in which

    A, R1, R2 and R3 are as defined in the description,

and the active compound groups (2) to (23) listed in the description have very good fungicidal properties.

## Background
The present invention relates to novel active compound combinations comprising firstly known carboxamides and secondly further known fungicidally active compounds, which novel active compound combinations are highly suitable for controlling unwanted phytopathogenic fungi.
It is already known that certain carboxamides have fungicidal properties. Thus, for example, N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide is known from DE-A 102 15 292, 3-trifluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4-carboxamide is known from WO 02/08197 and N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide is known WO 00/14701. The activity of these compounds is good; however, at low application rates it is sometimes unsatisfactory. Furthermore, it is already known that numerous triazole derivatives, aniline derivatives, dicarboximides and other heterocycles can be used for controlling fungi (cf. EP-A 0 040 345, DE-A 22 01 063, DE-A 23 24 010, Pesticide Manual, 9th Edition (1991), pages 249 and 827, EP-A 0 382 375 and EP-A 0515 901). However, the action of these compounds is likewise not always sufficient at low application rates. Furthermore, it is already known that 1-(3,5-dimethylisoxazole-4-sulphonyl)-2-chloro-6,6-difluoro-[1,3]-dioxolo-[4,5]-benzimidazole has fungicidal properties (cf. WO 97/06171). Finally, it is also known that substituted halopyrimidines have fungicidal properties (cf. DE-A1-196 46 407, EP-B 0 712 396).
The present invention now provides novel active compound combinations having very good fungicidal properties and comprising a carboxamide of the general formula (I) (group 1)




in which

    R1 represents hydrogen or fluorine,
    R2 represents halogen, C1-C3-alkyl, C1-C3-haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms, C1-C3-alkoxy, C1-C3-haloalkoxy having 1 to 7 fluorine, chlorine and/or bromine atoms or represents —C(R4)═N—OR5,
    R3 represents hydrogen, halogen, C1-C3-alkyl or C1-C3-haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
    R4 represents hydrogen or methyl,
    R5 represents C1-C5-alkyl, C1-C5-alkenyl or C1-C5-alkynyl,
    A represents one of the radicals A1 to A7 below:






    R6 represents C1-C3-alklyl,
    R7 represents hydrogen, halogen, C1-C3-alkyl or C1-C3-haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
    R8 represents hydrogen, halogen or C1-C3-alkyl,
    R9 represents hydrogen, halogen, C1-C3-alkyl, amino, mono- or di(C1-C3-alkyl)amino,
    R10 represents hydrogen, halogen, C1-C3-alkyl or C1-C3-haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
    R11 represents halogen, C1-C3-alkyl or C1-C3-haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
    R12 represents halogen, C1-C3-alkyl or C1-C3-haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
    R13 represents hydrogen, halogen, C1-C3-alkyl or C1-C3-haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,

and at least one active compound selected from groups (2) to (23) below:

Group (2) Strobilurins of the General Formula (II)







in which

    A1 represents one of the groups






    A2 represents NH or O,
    A3 represents N or CH,
    L represents one of the groups






    
    
        where the bond marked with an asterisk (*) is attached to the phenyl ring,
    
    
    R14 represents phenyl, phenoxy or pyridinyl, each of which is optionally mono- or disubstituted by identical or different substituents from the group consisting of chlorine, cyano, methyl and trifluoromethyl, or represents 1-(4-chlorophenyl)-pyrazol-3-yl or represents 1,2-propanedione-bis(O-methyloxime)-1-yl,
    R15 represents hydrogen or fluorine;

Group (3) Triazoles of the General Formula (III)







in which

    Q represents hydrogen or SH,
    m represents 0 or 1,
    R16 represents hydrogen, fluorine, chlorine, phenyl or 4-chlorophenoxy,
    R17 represents hydrogen or chlorine,
    A4 represents a direct bond, —CH2—, —(CH2)2— or —O—,
    A4 furthermore represents *—CH2—CHR20— or *—CH═CR20— where the bond marked with * is attached to the phenyl ring, and
    
        R18 and R20 furthermore together represent —CH2—CH2—CH[CH(CH3)2]— or —CH2—CH2—C(CH3)2—,
    
    
    A5 represents C or Si (silicon),
    A4 further represents —N(R2)— and A5 furthermore together with R18 and R19 represents the group C═N—R21, in which case R20 and R21 together represent the group






where the bond marked with * is attached to R20,

    R18 represents hydrogen, hydroxyl or cyano,
    R19 represents 1-cyclopropylethyl, 1-chlorocyclopropyl, C1-C4-alkyl, C1-C6-hydroxyalkyl, C1-C4-alkylcarbonyl, C1-C2-haloalkoxy-C1-C2-alkyl, trimethylsilyl-C1-C2-alkyl, monofluorophenyl or phenyl,
    R18 and R19 furthermore together represent —O—CH2—CH(R21)—O—, —O—CH2—CH(R21)—CH2—, or —O—CH(2-chlorophenyl)-,
    R21 represents hydrogen, C1-C4-alkyl or bromine;

Group (4) Sulphenamides of the General Formula (IV)







in which R22 represents hydrogen or methyl;












Group (5)
Valinamides selected from







(5-1)
iprovalicarb


(5-2)
N1-[2-(4-{[3-(4-chlorophenyl)-2-propynyl]oxy}-



3-methoxyphenyl)ethyl]-N2-(methylsulphonyl)-D-valinamide


(5-3)
benthiavalicarb









Group (6) Carboxamides of the General Formula (V)





in which

    X represents 2-chloro-3-pyridinyl, represents 1-methylpyrazol-4-yl which is substituted in the 3-position by methyl or trifluoromethyl and in the 5-position by hydrogen or chlorine, represents 4-ethyl-2-ethylamino-1,3-thiazol-5-yl, represents 1-methylcyclohexyl, represents 2,2-dichloro-1-ethyl-3-methylcyclopropyl, represents 2-fluoro-2-propyl or represents phenyl which is mono- to trisubstituted by identical or different substituents from the group consisting of chlorine and methyl,
    X furthermore represents 3,4-dichloroisothiazol-5-yl, 5,6-dihydro-2-methyl-1,4-oxathiin-3-yl, 4-methyl-1,2,3-thiadiazol-5-yl, 4,5-dimethyl-2-trmethylsilylthiophen-3-yl, 1-methylpyrrol-3-yl which is substituted in the 4-position by methyl or trifluoromethyl and in the 5-position by hydrogen or chlorine,
    Y represents a direct bond, C1-C6-alkanediyl (alkylene) which is optionally substituted by chlorine, cyano or oxo or represents thiophenediyl,
    Y furthermore represents C2-C6-alkenediyl (alkenylene),
    Z represents hydrogen or the group






    Z furthermore represents C1-C6-alkyl,
    A6 represents CH or N,
    R23 represents hydrogen, chlorine, phenyl which is optionally mono- or disubstituted by identical or different substituents from the group consisting of chlorine and di(C1-C3-alkyl)aminocarbonyl,
    R23 furthermore represents cyano or C1-C6-alkyl,
    R24 represents hydrogen or chlorine,
    R25 represents hydrogen, chlorine, hydroxyl, methyl or trifluoromethyl,
    R25 furthermore represents di(C1-C3-alkyl)aminocarbonyl,
    R23 and R24 furthermore together represent *—CH(CH3)—CH2—C(CH3)2— or *—CH(CH3)—OC(CH3)2— where the bond marked with * is attached to R23;
















Group (7)
Dithiocarbamates selected from









(7-1)
mancozeb



(7-2)
maneb



(7-3)
metiram



(7-4)
propineb



(7-5)
thiram



(7-6)
zineb



(7-7)
ziram










Group (8) Acylalanines of the General Formula (VI)





in which

    * marks a carbon atom in the R or the S configuration, preferably in the S configuration,
    R26 represents benzyl, furyl or methoxymethyl;

Group (9): Anilinopyrimidines of the General Formula (VII)







in which

    R27 represents methyl, cyclopropyl or 1-propynyl;

Group (10) Benzimidazoles of the General Formula (VIII)







in which

    R28 and R29 each represent hydrogen or together represent —O—CF2—O—,
    R30 represents hydrogen, C1-C4-alkylaminocarbonyl or represents 3,5-dimethylisoxazo-4-ylsulphonyl,
    R31 represents chlorine, methoxycarbonylamino, chlorophenyl, furyl or thiazolyl;

Group (11): Carbamates of the General Formula (XI)







in which

    R32 represents n- or isopropyl,
    R33 represents di(C1-C2-alkyl)amino-C2-C4-alkyl or diethoxyphenyl,

salts of these compounds also being included;

















Group (12):
Dicarboximides selected from









(12-1)
captafol



(12-2)
captan



(12-3)
folpet



(12-4)
iprodione



(12-5)
procymidone



(12-6)
vinclozolin
























Group (13):
Guanidines selected from









(13-1)
dodine



(13-2)
guazatine



(13-3)
iminoctadine triacetate



(13-4)
iminoctadine tris(albesilate)
























Group (14):
Imidazoles selected from









(14-1)
cyazofamid



(14-2)
prochloraz



(14-3)
triazoxide



(14-4)
pefurazoate










Group (15): Morpholines of the General Formula (X)





in which

    R34 and R35 independently of one another represent hydrogen or methyl,
    R36 represents C1-C14-alkyl (preferably C12-C14-alkyl), C5-C12-cycloalkyl (preferably C10-C12-cycloalkyl), phenyl-C1-C4-alkyl, which may be substituted in the phenyl moiety by halogen or C1-C4-alkyl or represents acrylyl which is substituted by chlorophenyl and dimethoxyphenyl;

Group (16): Pyrroles of the General Formula (XI)







in which

    R37 represents chlorine or cyano,
    R38 represents chlorine or nitro,
    R39 represents chlorine,
    R38 and R39 furthermore together represent —O—CF2—O—;
















Group (17):
Phosphonates selected from









(17-1)
fosetyl-Al



(17-2)
phosphonic acid;










Group (18): Phenylethanamides of the General Formula (XII)





in which

    R40 represents unsubstituted or fluorine-, chlorine-, bromine-, methyl- or ethyl-substituted phenyl, 2-naphthyl, 1,2,3,4-tetrahydronaphthyl or indanyl;













Group (19):
Fungicides selected from







(19-1)
acibenzolar-S-methyl


(19-2)
chlorothalonil


(19-3)
cymoxanil


(19-4)
edifenphos


(19-5)
famoxadone


(19-6)
fluazinam


(19-7)
copper oxychloride


(19-8)
copper hydroxide


(19-9)
oxadixyl


(19-10)
spiroxamine


(19-11)
dithianon


(19-12)
metrafenone


(19-13)
fenamidone


(19-14)
2,3-dibutyl-6-chlorothieno[2,3-d]pyrimidin-4(3H)-one


(19-15)
probenazole


(19-16)
isoprothiolane


(19-17)
kasugamycin


(19-18)
phthalide


(19-19)
ferimzone


(19-20)
tricyclazole


(19-21)
N-({4-[(cyclopropylamino)carbonyl]phenyl}sulphonyl)-2-



methoxybenzamide


(19-22)
2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-



yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide























Group (20):
(Thio)urea derivatives selected from









(20-1)
pencycuron



(20-2)
thiophanate-methyl



(20-3)
thiophanate-ethyl










Group (21): Amides of the General Formula (XIII)





in which

    A7 represents a direct bond or —O—,
    A8 represents —C(═O)NH— or —NHC(═O)—,
    R41 represents hydrogen or C1-C4-alkyl,
    R42 represents C1-C6-alkyl;

Group (22): Triazolopyrimidines of the General Formula (XIV)







in which

    R43 represents C1-C6-alkyl or C2-C6-alkenyl,
    R44 represents C1-C6-alkyl,
    R43 and R44 furthermore together represent C4-C5-alkanediyl (alkylene) which is mono- or disubstituted by C1-C6-alkyl,
    R45 represents bromine or chlorine,
    R46 and R50 independently of one another represent hydrogen, fluorine, chlorine or methyl,
    R47 and R49 independently of one another represent hydrogen or fluorine,
    R48 represents hydrogen, fluorine or methyl,

Group (23): Iodochromones of the General Formula (XV)







in which

    R51 represents C1-C6-alkyl,
    R52 represents C1-C6-alkyl, C2-C6-alkenyl or C2-C6-alkynyl.


Surprisingly, the fungicidal action of the active compound combinations according to the invention is considerably better than the sum of the activities of the individual active compounds. Thus, an unforeseeable true synergistic effect is present, and not just an addition of actions.
The formula (I) provides a general definition of the compounds of group (1).
Preference is given to carboxamides of the formula (I) in which

    R1 represents hydrogen or fluorine,
    R2 represents fluorine, chlorine, bromine, iodine, methyl, trifluoromethyl, trifluoromethoxy or represents —C(R4)═N—OR5,
    R3 represents hydrogen, fluorine, chlorine, bromine, methyl or trifluoromethyl,
    R4 represents hydrogen or methyl,
    R5 represents C1-C5-alkyl,
    A represents one of the radicals A1 to A7 below:






    R6 represents methyl,
    R7 represents iodine, methyl, difluoromethyl or trifluoromethyl,
    R8 represents hydrogen, fluorine, chlorine or methyl,
    R9 represents hydrogen, chlorine, methyl, amino or dimethylamino,
    R10 represents methyl, difluoromethyl or trifluoromethyl,
    R11 represents chlorine, bromine, iodine, methyl, difluoromethyl or trifluoromethyl,
    R12 represents bromine or methyl,
    R13 represents methyl or trifluoromethyl.


Particular preference is given to carboxamides of the formula (I) in which

    R1 represents hydrogen or fluorine,
    R2 represents fluorine, chlorine, bromine, trifluoromethyl or represents —CH═N—OCH3,
    R3 represents hydrogen, fluorine or chlorine,
    A represents one of the radicals A1 to A5 below:






    R6 represents methyl,
    R7 represents methyl, difluoromethyl or trifluoromethyl,
    R8 represents hydrogen or fluorine,
    R9 represents methyl,
    R10 represents methyl, difluoromethyl or trifluoromethyl,
    R11 represents iodine, difluoromethyl or trifluoromethyl,
    R12 represents methyl,
    R13 represents methyl or trifluoromethyl.


Very particular preference is given to carboxamides of the formula (I) in which

    R1 represents hydrogen or fluorine,
    R2 represents fluorine, chlorine, bromine, trifluoromethyl or represents —CH═N—OCH3,
    R3 represents hydrogen, fluorine or chlorine,
    A represents one of the radicals A1 or A2 below:






    R6 represents methyl,
    R7 represents methyl, difluoromethyl or trifluoromethyl,
    R8 represents hydrogen or fluorine,
    R9 represents methyl,
    R10 represents methyl, difluoromethyl or trifluoromethyl.


Very particular preference is given to using, in mixtures, compounds of the formula (Ia)




in which R1, R2, R3, R6, R7 and R8 are as defined above.

Very particular preference is given to using, in mixtures, compounds of the formula (Ib)




in which R1, R2, R3, R9 and R10 are as defined above.

The formula (I) embraces in particular the following preferred mixing partners of group (1):

    (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide (known from WO 03/070705)
    (1-2) 3-difluoromethyl)-N-{3′-fluoro-4′-[(E)-methoxyimino)methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4-carboxamide (known from WO 02/08197)
    (1-3) 3-trifluoromethyl)-N-{3′-fluoro-4′-[(E)-methoxyimino)methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4-carboxamide (known from WO 02/08197)
    (1-4) N-3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide (known from WO 00/14701)
    (1-5) N-4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-methyl-4-trifluoromethyl)-1,3-thiazole-5-carboxamide (known from WO 03/066609)
    (1-6) N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide (known from WO 03/066610)
    (1-7) N-4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide (known from WO 03/066610)
    (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide (known from WO 03/066610)
    (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide (known from WO 03/066610)


Emphasis is given to active compound combinations according to the invention which, in addition to carboxamide (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide (group 1) comprise one or more, preferably one, mixing partner of groups (2) to (23).
Emphasis is given to active compound combinations according to the invention which, in addition to carboxamide (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide (group 1) comprise one or more, preferably one, mixing partner of groups (2) to (23).
Emphasis is given to active compound combinations according to the invention which, in addition to carboxamide (1-8) 4-difluoromethyl)-2-methyl-N-[4′-trifluoromethyl)-1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide (group 1) comprise one or more, preferably one, mixing partner of groups (2) to (23).
Emphasis is given to active compound combinations according to the invention which, in addition to carboxamide (1-9) N-(4-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide (group 1) comprise one or more, preferably one, mixing partner of groups (2) to (23).
The formula (II) embraces the following preferred mixing partners of group (2):

    (2-1) azoxystrobin (known from EP-A 0 382 375) of the formula






    (2-2) fluoxastrobin (known from DE-A 196 02 095) of the formula






    (2-3) (2E)-2-(2-{[6-(3-chloro-2-methylphenoxy)-5-fluoro-4-pyrimidinyl]oxy}phenyl)-2-(methoxyimino)-N-methylethanamide (known from DE-A 196 46 407, EP-B 0 712 396) of the formula






    (2-4) trifloxystrobin (known from EP-A 0 460 575) of the formula






    (2-5) (2E)-2-methoxyimino)-N-methyl-2-(2-{[({(E)-1-[3-(trifluoromethyl)phenyl]ethylidene}-amino)oxy]methyl}phenyl)ethanamide (known from EP-A 0 569 384) of the formula






    (2-6) (2E)-2-methoxyimino)-N-methyl-2-{2-[(E)-({1-[3-trifluoromethyl)phenyl)ethoxy}imino)methyl]phenyl}ethanamide (known from EP-A 0 596 254) of the formula






    (2-7) orysastrobin (known from DE-A 195 39 324) of the formula






    (2-8) 5-methoxy-2-methyl-4-(2-{[({(1E)-1-[3-trifluoromethyl)phenyl]ethylidene}amino)oxy]-methyl}phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (known from WO 98/23155) of the formula






    (2-9) kresoxim-methyl (known from EP-A 0 253 213) of the formula






    (2-10) dimoxystrobin (known from EP-A 0 398 692) of the formula






    (2-11) picoxystrobin (known from EP-A 0 278 595) of the formula






    (2-12) pyraclostrobin (known from DE-A 44 23 612) of the formula






    (2-13) metominostrobin (known from EP-A 0 398 692) of the formula






The formula (III) embraces the following preferred mixing partners of group (3):

    (3-1) azaconazole (known from DE-A 25 51 560) of the formula






    (3-2) etaconazole (known from DE-A 25 51 560) of the formula






    (3-3) propiconazole (known from DE-A 25 51 560) of the formula






    (34) difenoconazole (known from EP-A 0 112 284) of the formula






    (3-5) bromuconazole (known from EP-A 0 258 161) of the formula






    (3-6) cyproconazole (known from DE-A 34 06 993) of the formula






    (3-7) hexaconazole (known from DE-A 30 42 303) of the formula






    (3-8) penconazole (known from DE-A 27 35 872) of the formula






    (3-9) myclobutanil (known from EP-A 0 145 294) of the formula






    (3-10) tetraconazole (known from EP-A 0 234 242) of the formula






    (3-11) flutriafol (known from EP-A 0 015 756) of the formula






    (3-12) epoxiconazole (known from EP-A 0 196 038) of the formula






    (3-13) flusilazole (known from EP-A 0 068 813) of the formula






    (3-14) simeconazole (known from EP-A 0 537 957) of the formula






    (3-15) prothioconazole (known from WO 96/16048) of the formula






    (3-16) fenbuconazole (known from DE-A 37 21 786) of the formula






    (3-17) tebuconazole (known from EP-A 0 040 345) of the formula






    (3-18) ipconazole (known from EP-A 0 329 397) of the formula






    (3-19) metconazole (known from EP-A 0 329 397) of the formula






    (3-20) triticonazole (known from EP-A 0 378 953) of the formula






    (3-21) bitertanol (known from DE-A 23 24 010) of the formula






    (3-22) triadimenol (known from DE-A 23 24 010) of the formula






    (3-23) triadimefon (known from DE-A 22 01 063) of the formula






    (3-24) fluquinconazole (known from EP-A 0 183 458) of the formula






    (3-25) quinconazole (known from EP-A 0 183 458) of the formula






The formula (IV) embraces the following preferred mixing partners of group (4):

    (4-1) dichlofluanid (known from DE-A 11 93 498) of the formula






    (4-2) tolylfluanid (known from DE-A 11 93 498) of the formula






Preferred mixing partners of group (5) are

    (5-1) iprovalicarb (known from DE-A 40 26 966) of the formula






    (5-3) benthiavalicarb (known from WO 96/04252) of the formula






The formula (V) embraces the following preferred mixing partners of group (6):

    (6-1) 2-chloro-N-(1,1,3-trimethylindan-4-yl)nicounamide (known from EP-A 0 256 503) of the formula






    (6-2) boscalid (known from DE-A 195 31 813) of the formula






    (6-3) furametpyr (known from EP-A 0 315 502) of the formula






    (6-4) N-(3-p-tolylthiophen-2-yl)-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide (known from EP-A 0 737 682) of the formula






    (6-5) ethaboxam (known from EP-A 0 639 574) of the formula






    (6-6) fenhexamid (known from EP-A 0 339 418) of the formula






    (6-7) carpropamid (known from EP-A 0 341 475) of the formula






    (6-8) 2-chloro-4-(2-fluoro-2-methylpropionylamino)-N,N-dimethylbenzamide (known from EP-A 0 600 629) of the formula






    (6-9) picobenzamid (known from WO 99/42447) of the formula






    (6-10) zoxamide (known from EP-A 0 604 019) of the formula






    (6-11) 3,4-dichloro-N-(2-cyanophenyl)isothiazole-5-carboxamide (known from WO 99/24413) of the formula






    (6-12) carboxin (known from U.S. Pat. No. 3,249,499) of the formula






    (6-13) tiadinil (known from U.S. Pat. No. 6,616,054) of the formula






    (6-14) penthiopyrad (known from EP-A 0 737 682) of the formula






    (6-15) silthiofam (known from WO 96/18631) of the formula






    (6-16) N-[2-(1,3-dimethylbutyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide (known from WO 02/38542) of the formula






Preferred mixing partners of group (7) are

    (7-1) mancozeb (known from DE-A 12 34 704) having the IUPAC name manganese ethylenebis(dithiocarbamate) (polymeric) complex with zinc salt
    (7-2) maneb (known from U.S. Pat. No. 2,504,404) of the formula






    (7-3) metiram (known from DE-A 10 76 434) having the IUPAC name zinc ammoniate ethylenebis(dithiocarbamate)-poly(ethylenethiuram disulphide)
    (74) propineb (known from GB 935 981) of the formula






    (7-5) thiram (known from U.S. Pat. No. 1,972,961) of the formula






    (7-6) zineb (known from DE-A 10 81 446) of the formula






    (7-7) ziram (known from U.S. Pat. No. 2,588,428) of the formula






The formula (VI) embraces the following preferred mixing partners of group (8):

    (8-1) benalaxyl (known from DE-A 2903 612) of the formula






    (8-2) furalaxyl (known from DE-A 25 13 732) of the formula






    (8-3) metalaxyl (known from DE-A 25 15 091) of the formula






    (8-4) metalaxyl-M (known from WO 96/01559) of the formula






    (8-5) benalaxyl-M of the formula






The formula (VII) embraces the following preferred mixing partners of group (9):

    (9-1) cyprodinil (known from EP-A 0 310 550) of the formula






    (9-2) mepanipyrim (known from EP-A 0 270 111) of the formula






    (9-3) pyrimethanil (known from DD 151 404) of the formula






The formula (VIII) embraces the following preferred mixing partners of group (10):

    (10-1) 6-chloro-5-[(3,5-dimethylisoxazol-4-yl)sulphonyl]-2,2-difluoro-5H-[1,3]dioxolo[4,5-f]-benzimidazole (known from WO 97/06171) of the formula






    (10-2) benomyl (known from U.S. Pat. No. 3,631,176) of the formula






    (10-3) carbendazim (known from U.S. Pat. No. 3,010,968) of the formula






    (104) chlorfenazole of the formula






    (10-5) fuberidazole (known from DE-A 12 09 799) of the formula






    (10-6) thiabendazole (known from U.S. Pat. No. 3,206,468) of the formula






The formula (IX) embraces the following preferred mixing partners of group (11):

    (11-1) diethofencarb (known from EP-A 0 078 663) of the formula






    (11-2) propamocarb (known from U.S. Pat. No. 3,513,241) of the formula






    (11-3) propamocarb-hydrochloride (known from U.S. Pat. No. 3,513,241) of the formula






    (11-4) propamocarb-fosetyl of the formula






Preferred mixing partners of group (12) are

    (12-1) captafol (known from U.S. Pat. No. 3,178,447) of the formula






    (12-2) captan (known from U.S. Pat. No. 2,553,770) of the formula






    (12-3) folpet (known from U.S. Pat. No. 2,553,770) of the formula






    (12-4) iprodione (known from DE-A 21 49 923) of the formula






    (12-5) procymidone (known from DE-A 20 12 656) of the formula






    (12-6) vinclozolin (known from DE-A 22 07 576) of the formula






Preferred mixing partners of group (13) are

    (13-1) dodine (known from GB 11 03 989) of the formula






    (13-2) guazatine (known from GB 11 14 155)
    (13-3) iminoctadine triacetate (known from EP-A 0 155 509) of the formula






Preferred mixing partners of the group (14) are

    (14-1) cyazofamid (known from EP-A 0 298 196) of the formula






    (14-2) prochloraz (known from DE-A 24 29 523) of the formula






    (14-3) triazoxide (known from DE-A 28 02 488) of the formula






    (14-4) pefurazoate (known from EP-A 0 248 086) of the formula






The formula (X) embraces the following preferred mixing partners of group (15):

    (15-1) aldimorph (known from DD 140 041) of the formula






    (15-2) tridemorph (known from GB 988 630) of the formula






    (15-3) dodemorph (known from DE-A 25 432 79) of the formula






    (15-4) fenpropimorph (known from DE-A 26 56 747) of the formula






    (15-5) dimethomorph (known from EP-A 0219 756) of the formula






The formula (XI) embraces the following preferred mixing partners of group (16):

    (16-1) fenpiclonil (known from EP-A 0 236 272) of the formula






    (16-2) fludioxonil (known from EP-A 0 206 999) of the formula






    (16-3) pyrrolnitrin (known from JP 65-25876) of the formula






Preferred mixing partners of group (17) are

    (17-1) fosetyl-Al (known from DE-A 2456627) of the formula






    (17-2) phosphonic acid (known chemical) of the formula






The formula (XII) embraces the following preferred mixing partners of group (18) which are known from WO 96/23793 and can in each case be present as E or Z isomers. Accordingly, compounds of the formula (XII) can be present as a mixture of different isomers or else in the form of a single isomer. Preference is given to compounds of the formula (XI) in the form of their E isomers:

    (18-1) 2-(2,3-dihydro-1H-inden-5-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(methoxyimino)acetamide of the formula






    (18-2) N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(methoxyimino)-2-(5,6,7,8-tetrahydronaphthalen-2-yl)acetamide of the formula






    (18-3) 2-(4-chlorophenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(methoxyimino)acetamide of the formula






    (18-4) 2-(4-bromophenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(methoxyimino)acetamide of the formula






    (18-5) 2-(4-methylphenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(methoxyimino)acetamide of the formula






    (18-6) 2-(4-ethylphenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(methoxyimino)acetamide of the formula






(Preferred mixing partners of group (19) are

    (19-1) acibenzolar-S-methyl (known from EP-A 0 313 512) of the formula






    (19-2) chlorothalonil (known from U.S. Pat. No. 3,290,353) of the formula






    (19-3) cymoxanil (known from DE-A 23 12 956) of the formula






    (19-4) edifenphos (known from DE-A 14 93 736) of the formula






    (19-5) famoxadone (known from EP-A 0 393 911) of the formula






    (19-6) fluazinam (known from EP-A 0031 257) of the formula






    (19-7) copper oxychloride
    (19-9) oxadixyl (known from DE-A 30 30 026) of the formula






    (19-10) spiroxamine (known from DE-A 37 35 555) of the formula






    (19-11) dithianon (known from JP-A 44-29464) of the formula






    (19-12) metrafenone (known from EP-A 0 0897 904) of the formula






    (19-13) fenamidone (known from EP-A 0 629 616) of the formula






    (19-14) 2,3-dibutyl-chlorothieno[2,3-d]pyrimidin-4-(3H)one (known from WO 99/14202) of the formula






    (19-15) probenazole (known from U.S. Pat. No. 3,629,428) of the formula






    (19-16) isoprothiolane (known from U.S. Pat. No. 3,856,814) of the formula






    (19-17) kasugamycin (known from GB 1 094567) of the formula






    (19-18) phthalide (known from JP-A 57-55844) of the formula






    (19-19) ferimzone (known from EP-A 0 019450) of the formula






    (19-20) tricyclazole (known from DE-A 22 50077) of the formula






    (19-21) N-({4-[(cyclopropylamino)carbonyl]phenyl}sulphonyl)-2-methoxybenzamide of the formula






    (19-22) 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide (known from WO 01/87822) of the formula






Preferred mixing partners of group (20) are

    (20-1) pencycuron (known from DE-A 27 32 257) of the formula






    (20-2) thiophanate-methyl (known from DE-A 18 06 123) of the formula






    (20-3) thiophanate-ethyl (known from DE-A 18 06 123) of the formula






Preferred mixing partners of group (21) are

    (21-1) fenoxanil (known from EP-A 0262393) of the formula






    (21-2) diclocymet (known from JP-A 7-206608) of the formula






Preferred mixing partners of group (22) are

    (22-1) 5-chloro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo-[1,5-a]pyrimidine-7-amine (known from U.S. Pat. No. 5,986,135) of the formula






    (22-2) 5-chloro-N-[(1R)-1,2-dimethylpropyl]-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]-(pyrimidine-7-amine (known from WO 02/38565) of the formula






    (22-3) 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]-pyrimidine (known from U.S. Pat. No. 5,593,996) of the formula






    (22-4) 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine (known from DE-A 101 24 208) of the formula






Preferred mixing partners of group (23) are

    (23-1) 2-butoxy-6-iodo-3-propylbenzopyran-4-one (known from WO 03/014103) of the formula






    (23-2) 2-ethoxy-6-iodo-3-propylbenzopyran-4-one (known from WO 03/014103) of the formula






    (23-3) 6-iodo-2-propoxy-3-propylbenzopyran-4-one (known from WO 03/014103) of the formula






    (23-4) 2-but-2-ynyloxy-6-iodo-3-propylbenzopyran-4-one (known from WO 03/014103) of the formula






    (23-5) 6-iodo-2-(1-methylbutoxy)-3-propylbenzopyran-4-one (known from WO 03/014103) of the formula






    (23-6) 2-but-3-enyloxy-6-iodobenzopyran-4-one (known from WO 03/014103) of the formula






    (23-7) 3-butyl-6-iodo-2-isopropoxybenzopyran-4-one (known from WO 03/014103) of the formula






Compound (6-7), carpropamid, has three asymmetrically substituted carbon atoms. Accordingly, compound (6-7) can be present as a mixture of different isomers or else in the form of a single component. Particular preference is given to the compounds

    (1S,3R)-2,2-dichloro-N-[(1R)-1-(4-chlorophenyl)ethyl]-1-ethyl-3-methylcyclopropanecarboxamide of the formula






    (1R,3S)-2,2-dichloro-N-[(1R)-1-(4-chlorophenyl)ethyl]-1-ethyl-3-methylcyclopropanecarboxamide of the formula






Particularly preferred mixing partners are the following active compounds:

    (2-1) azoxystrobin
    (2-2) fluoxastrobin
    (2-3) (2E)-2-(2-{[6-(3-chloro-2-methylphenoxy)-5-fluoro-4-pyrimnidinyl]oxy}phenyl)-2-(methoxyimino)-N-methylethanamide
    (2-4) trifloxystrobin
    (2-5) (2E)-2-(methoxyimino)-N-methyl-2-(2-{[({(1E)-1-[3-(trifluoromethyl)phenyl]ethylidene}amino)oxy]methyl}phenyl)ethanamide
    (2-6) (2E)-2-(methoxyimino)-N-methyl-2-{2-[(E)-({1-[3-(trifluoromethyl)phenyl]-ethoxy}imino)methyl]phenyl}ethanamide
    (2-8) 5-methoxy-2-methyl-4-(2-{[({(1E)-1-[3-(trifluoromethyl)phenyl]ethylidene}-amino)oxy]methyl}phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one
    (2-11) picoxystrobin
    (2-9) kresoxim-methyl
    (2-10) dimoxystrobin
    (2-12) pyraclostrobin
    (2-13) metominostrobin
    (3-3) propiconazole
    (3-4) difenoconazole
    (3-6) cyproconazole
    (3-7) hexaconazole
    (3-8) penconazole
    (3-9) myclobutanil
    (3-10) tetraconazole
    (3-13) flusilazole
    (3-15) prothioconazole
    (3-16) fenbuconazole
    (3-17) tebuconazole
    (3-21) bitertanol
    (3-22) triadimenol
    (3-23) triadimefon
    (3-12) epoxiconazole
    (3-19) metconazole
    (3-24) fluquinconazole
    (4-1) dichlofluanid
    (4-2) tolylfluanid
    (5-1) iprovalicarb
    (5-3) benthiavalicarb
    (6-2) boscalid
    (6-5) ethaboxam
    (6-6) fenhexamid
    (6-7) carpropamid
    (6-8) 2-chloro-4-[(2-fluoro-2-methylpropanoyl)amino]-N,N-dimethylbenzamide
    (6-9) picobenzamid
    (6-10) zoxamide
    (6-11) 3,4-dichloro-N-(2-cyanophenyl)isothiazole-5-carboxamide
    (6-14) penthiopyrad
    (6-16) N-[2-(1,3-dimethylbutyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide
    (7-1) mancozeb
    (7-2) maneb
    (7-4) propineb
    (7-5) thiram
    (7-6) zineb
    (8-1) benalaxyl
    (8-2) furalaxyl
    (8-3) metalaxyl
    (8-4) metalaxyl-M
    (8-5) benalaxyl-M
    (9-1) cyprodinil
    (9-2) mepanipyrim
    (9-3) pyrimethanil
    (10-1) 6-chloro-5-[(3,5-dimethylisoxazol-4-yl)sulphonyl]-2,2-difluoro-5H-[1,3]dioxolo[4,5-f]-benzimidazole
    (10-3) carbendazim
    (11-1) diethofencarb
    (11-2) propamocarb
    (11-3) propamocarb-hydrochloride
    (11-4) propamocarb-fosetyl
    (12-2) captan
    (12-3) folpet
    (12-4) iprodione
    (12-5) procymidone
    (13-1) dodine
    (13-2) guazatine
    (13-3) iminoctadine triacetate
    (14-1) cyazofamid
    (14-2) prochloraz
    (14-3) triazoxide
    (15-5) dimethomorph
    (15-4) fenpropimorph
    (16-2) fludioxonil
    (17-1) fosetyl-Al
    (17-2) phosphonic acid
    (19-1) acibenzolar-S-methyl
    (19-2) chlorothalonil
    (19-3) cymoxanil
    (19-5) famoxadone
    (19-7) copper oxychloride
    (19-6) fluazinam
    (19-9) oxadixyl
    (19-10) spiroxamine
    (19-13) fenamidone
    (19-22) 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide
    (20-1) pencycuron
    (20-2) thiophanate-methyl
    (22-1) 5-chloro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-trifluorophenyl)[1,2,4]-triazolo[1,5-a]pyrimidine-7-amine
    (22-2) 5-chloro-N-[(1R)-1,2-dimethylpropyl]-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]-pyrimidine-7-amine
    (22-4) 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine
    (23-1) 2-butoxy-6-iodo-3-propylbenzopyran-4-one
    (23-2) 2-ethoxy-6-iodo-3-propylbenzopyran-4-one
    (23-3) 6-iodo-2-propoxy-3-propylbenzopyran-4-one


Very particularly preferred mixing partners are the following active compounds:

    (2-2) fluoxastrobin
    (2-3) (2E)-2-(2-{[6-(3-chloro-2-methylphenoxy)-5-fluoro-4-pyrimidinyl]oxy}phenyl)-2-methoxyimino)-N-methylethanamide
    (2-4) trifloxystrobin
    (3-15) prothioconazole
    (3-17) tebuconazole
    (3-21) bitertanol
    (3-22) triadimenol
    (3-24) fluquinconazole
    (4-1) dichlofluanid
    (4-2) tolylfluanid
    (5-1) iprovalicarb
    (6-6) fenhexamid
    (6-7) carpropamid
    (6-9) picobenzamid
    (6-14) penthiopyrad
    (7-4) propineb
    (8-4) metalaxyl-M
    (8-5) benalaxyl-M
    (9-3) pyrimethanil
    (10-3) carbendazim
    (11-4) propamocarb-fosetyl
    (12-4) iprodione
    (14-2) prochloraz
    (14-3) triazoxide
    (16-2) fludioxonil
    (19-10) spiroxamine
    (19-22) 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide
    (22-4) 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine


Preferred active compound combinations consisting of two groups of active compounds and comprising in each case at least one carboxamide of the formula (I) (group 1) and at least one active compound from the stated group (2) to (23) are described below. These combinations are the active compound combinations A to T.
Among the preferred active compound combinations A to T, emphasis is given to those comprising a carboxamide of the formula (I) (group 1)




in which R1, R2, R3 and A are as defined above.

Particular preference is given to active compound combinations A to T comprising a carboxamide of the formula (I) (group 1)




in which

    R1 represents hydrogen or fluorine,
    R2 represents fluorine, chlorine, bromine, trifluoromethyl or represents —CH═N—OCH3,
    R3 represents hydrogen, fluorine or chlorine,
    A represents one of the radicals A1 or A2 below:






    R6 represents methyl,
    R7 represents methyl, difluoromethyl or trifluoromethyl,
    R8 represents hydrogen or fluorine,
    R9 represents methyl,
    R10 represents methyl, difluoromethyl or trifluoromethyl.


Very particular preference is given to active compound combinations A to T in which the carboxamide of the formula (I) (group 1) is selected from the list below:

    (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide
    (1-2) 3-(difluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4-carboxamide
    (1-3) 3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4-carboxamide
    (1-4) N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide
    (1-5) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-methyl-4-(trifluoromethyl)-1,3-thiazole-5-carboxamide
    (1-6) N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide
    (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide
    (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide
    (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide


Especially preferred are active compound combinations A to T in which the carboxamide of the formula (I) (group 1) is selected from the list below:

    (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide
    (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide
    (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide
    (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide.


In addition to a carboxamide of the formula (I) (group 1), the active compound combinations A also comprise a strobilurin of the formula (II) (group 2)




in which A1, L and R14 are as defined above.

Particular preference is given to active compound combinations A in which the strobilurin of the formula (II) (group 2) is selected from the list below:

    (2-1) azoxystrobin
    (2-2) fluoxastrobin
    (2-3) (2E)-2-(2-{[6-(3-chloro-2-methylphenoxy)-5-fluoro-4-pyrimidinyl]oxy}phenyl)-2-methoxyimino)-N-methylethanamide
    (2-4) trifloxystrobin
    (2-5) (2E)-2-methoxyimino)-N-methyl-2-(2-{[({(1E)-1-[3-(trifluoromethyl)phenyl]ethylidene}-amino)oxy]methyl}phenyl)ethanamide
    (2-6) (2E)-2-(methoxyimino)-N-methyl-2-{2-[(E)-({1-[3-(trifluoromethyl)phenyl]ethoxy}imino)methyl]phenyl}ethanamide
    (2-7) orysastrobin
    (2-8) 5-methoxy-2-methyl-4-(2-{[({(1E)-1-[3-trifluoromethyl)phenyl]ethylidene}amino)oxy]-methyl}phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one
    (2-9) kresoxim-methyl
    (2-10) dimoxystrobin
    (2-11) picoxystrobin
    (2-12) pyraclostrobin
    (2-13) metominostrobin


Very particular preference is given to active compound combinations A in which the strobilurin of the formula (II) (group 2) is selected from the list below:

    (2-1) azoxystrobin
    (2-2) fluoxastrobin
    (2-3) (2E)-2-(2-{[6-(3-chloro-2-methylphenoxy)-5-fluoro-4-pyrimidinyl]oxy}phenyl)-2-(methoxyimino)-N-methylethanamide
    (2-4) trifloxystrobin
    (2-12) pyraclostrobin
    (2-9) kresoxim-methyl
    (2-10) dimoxystrobin
    (2-11) picoxystrobin
    (2-13) metominostrobin


Emphasis is given to the active compound combinations A listed in Table 1 below:







TABLE 1







Active compound combinations A









No.
Carboxamide of the formula (I)
Strobilurin of the formula (II)





A-1
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(2-1) azoxystrobin



(difluoromethyl)-1-methyl-1H-pyrazole-4-



carboxamide


A-2
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(2-2) fluoxastrobin



(difluoromethyl)-1-methyl-1H-pyrazole-4-



carboxamide


A-3
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-
(2-3) (2E)-2-(2-{[6-(3-chloro-2-



3-(difluoromethyl)-1-methyl-1H-pyrazole-
methylphenoxy)-5-fluoro-4-pyrimidinyl]



4-carboxamide
oxy}phenyl)-2-(methoxyimino)-




N-methylethanamide


A-4
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(2-4) trifloxystrobin



(difluoromethyl)-1-methyl-1H-pyrazole-4-



carboxamide


A-5
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(2-12) pyraclostrobin



(difluoromethyl)-1-methyl-1H-pyrazole-4-



carboxamide


A-6
(1-2) 3-(difluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)
(2-1) azoxystrobin



methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-



pyrazole-4-carboxamide


A-7
(1-2) 3-(difluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)
(2-2) fluoxastrobin



methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-



pyrazole-4-carboxamide


A-8
(1-2) 3-(difluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)
(2-3) (2E)-2-(2-{[6-(3-chloro-2-



methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-
methylphenoxy)-5-fluoro-4-pyrimidinyl]



pyrazole-4-carboxamide
oxy}phenyl)-2-(methoxyimino)-




N-methylethanamide


A-9
(1-2) 3-(difluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)
(2-4) trifloxystrobin



methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-



pyrazole-4-carboxamide


A-10
(1-2) 3-(difluoromethyl)-N-{3′-fluoro-4-[(E)-(methoxyimino)
(2-12) pyraclostrobin



methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-



pyrazole-4-carboxamide


A-11
(1-3) 3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)
(2-1) azoxystrobin



methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-



pyrazole-4-carboxamide


A-12
(1-3) 3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)
(2-2) fluoxastrobin



methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-



pyrazole-4-carboxamide


A-13
(1-3) 3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)
(2-3) (2E)-2-(2-{[6-(3-chloro-2-



methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-
methylphenoxy)-5-fluoro-4-pyrimidinyl]



pyrazole-4-carboxamide
oxy}phenyl)-2-(methoxyimino)-




N-methylethanamide


A-14
(1-3) 3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)
(2-4) trifloxystrobin



methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-



pyrazole-4-carboxamide


A-15
(1-3) 3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)
(2-12) pyraclostrobin



methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-



pyrazole-4-carboxamide


A-16
(1-4) N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro-
(2-1) azoxystrobin



1,3-dimethyl-1H-pyrazole-4-carboxamide


A-17
(1-4) N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro-
(2-2) fluoxastrobin



1,3-dimethyl-1H-pyrazole-4-carboxamide


A-18
(1-4) N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro-
(2-3) (2E)-2-(2-{[6-(3-chloro-2-



1,3-dimethyl-1H-pyrazole-4-carboxamide
methylphenoxy)-5-fluoro-4-pyrimidinyl]




oxy}phenyl)-2-(methoxyimino)-




N-methylethanamide


A-19
(1-4) N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro-
(2-4) trifloxystrobin



1,3-dimethyl-1H-pyrazole-4-carboxamide


A-20
(1-4) N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro-
(2-12) pyraclostrobin



1,3-dimethyl-1H-pyrazole-4-carboxamide


A-21
(1-5) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-
(2-1) azoxystrobin



methyl-4-(trifluoromethyl)-1,3-thiazole-5-



carboxamide


A-22
(1-5) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-
(2-2) fluoxastrobin



methyl-4-(trifluoromethyl)-1,3-thiazole-5-



carboxamide


A-23
(1-5) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-
(2-3) (2E)-2-(2-{[6-(3-chloro-2-



methyl-4-(trifluoromethyl)-1,3-thiazole-5-
methylphenoxy)-5-fluoro-4-pyrimidinyl]



carboxamide
oxy}phenyl)-2-(methoxyimino)-




N-methylethanamide


A-24
(1-5) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-
(2-4) trifloxystrobin



methyl-4-(trifluoromethyl)-1,3-thiazole-5-



carboxamide


A-25
(1-5) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-
(2-12) pyraclostrobin



methyl-4-(trifluoromethyl)-1,3-thiazole-5-



carboxamide


A-26
(1-6) N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(2-1) azoxystrobin



2-methyl-1,3-thiazole-5-carboxamide


A-27
(1-6) N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(2-2) fluoxastrobin



2-methyl-1,3-thiazole-5-carboxamide


A-28
(1-6) N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(2-3) (2E)-2-(2-{[6-(3-chloro-2-



2-methyl-1,3-thiazole-5-carboxamide
methylphenoxy)-5-fluoro-4-pyrimidinyl]




oxy}phenyl)-2-(methoxyimino)-




N-methylethanamide


A-29
(1-6) N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(2-4) trifloxystrobin



2-methyl-1,3-thiazole-5-carboxamide


A-30
(1-6) N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(2-12) pyraclostrobin



2-methyl-1,3-thiazole-5-carboxamide


A-31
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(2-1) azoxystrobin



2-methyl-1,3-thiazole-5-carboxamide


A-32
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(2-2) fluoxastrobin



2-methyl-1,3-thiazole-5-carboxamide


A-33
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(2-3) (2E)-2-(2-{[6-(3-chloro-2-



2-methyl-1,3-thiazole-5-carboxamide
methylphenoxy)-5-fluoro-4-pyrimidinyl]




oxy}phenyl)-2-(methoxyimino)-




N-methylethanamide


A-34
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(2-4) trifloxystrobin



2-methyl-1,3-thiazole-5-carboxamide


A-35
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(2-12) pyraclostrobin



2-methyl-1,3-thiazole-5-carboxamide


A-36
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(2-1) azoxystrobin



1,1′-biphenyl-2-yl]-1,3-thiazole-5-



carboxamide


A-37
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(2-2) fluoxastrobin



1,1′-biphenyl-2-yl]-1,3-thiazole-5-



carboxamide


A-38
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(2-3) (2E)-2-(2-{[6-(3-chloro-2-



1,1′-biphenyl-2-yl]-1,3-thiazole-5-
methylphenoxy)-5-fluoro-4-pyrimidinyl]



carboxamide
oxy}phenyl)-2-(methoxyimino)-




N-methylethanamide


A-39
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(2-4) trifloxystrobin



1,1′-biphenyl-2-yl]-1,3-thiazole-5-



carboxamide


A-40
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(2-12) pyraclostrobin



1,1′-biphenyl-2-yl]-1,3-thiazole-5-



carboxamide


A-41
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(2-9) kresoxim-methyl



(difluoromethyl)-1-methyl-1H-pyrazole-4-



carboxamide


A-42
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(2-10) dimoxystrobin



(difluoromethyl)-1-methyl-1H-pyrazole-4-



carboxamide


A-43
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(2-11) picoxystrobin



(difluoromethyl)-1-methyl-1H-pyrazole-4-



carboxamide


A-44
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(2-13) metominostrobin



(difluoromethyl)-1-methyl-1H-pyrazole-4-



carboxamide


A-45
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(2-9) kresoxim-methyl



2-methyl-1,3-thiazole-5-carboxamide


A-46
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(2-10) dimoxystrobin



2-methyl-1,3-thiazole-5-carboxamide


A-47
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(2-11) picoxystrobin



2-methyl-1,3-thiazole-5-carboxamide


A-48
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(2-13) metominostrobin



2-methyl-1,3-thiazole-5-carboxamide


A-49
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(2-9) kresoxim-methyl



1,1′-biphenyl-2-yl]-1,3-thiazole-5-



carboxamide


A-50
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(2-10) dimoxystrobin



1,1′-biphenyl-2-yl]-1,3-thiazole-5-



carboxamide


A-51
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(2-11) picoxystrobin



1,1′-biphenyl-2-yl]-1,3-thiazole-5-



carboxamide


A-52
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(2-13) metominostrobin



1,1′-biphenyl-2-yl]-1,3-thiazole-5-



carboxamide


A-53
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-
(2-9) kresoxim-methyl



(difluoromethyl)-2-methyl-1,3-thiazole-5-



carboxamide


A-54
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-
(2-10) dimoxystrobin



(difluoromethyl)-2-methyl-1,3-thiazole-5-



carboxamide


A-55
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-
(2-11) picoxystrobin



(difluoromethyl)-2-methyl-1,3-thiazole-5-



carboxamide


A-56
(1-9) N-(4′-chloro-3′-fluoro-1,1-biphenyl-2-yl)-4-
(2-13) metominostrobin



(difluoromethyl)-2-methyl-1,3-thiazole-5-



carboxamide


A-57
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-
(2-1) azoxystrobin



(difluoromethyl)-2-methyl-1,3-thiazole-5-



carboxamide


A-58
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-
(2-2) fluoxastrobin



(difluoromethyl)-2-methyl-1,3-thiazole-5-



carboxamide


A-59
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-
(2-3) (2E)-2-(2-{[6-(3-chloro-2-



(difluoromethyl)-2-methyl-1,3-thiazole-5-
methylphenoxy)-5-fluoro-4-pyrimidinyl]



carboxamide
oxy}phenyl)-2-(methoxyimino)-




N-methylethanamide


A-60
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-
(2-4) trifloxystrobin



(difluoromethyl)-2-methyl-1,3-thiazole-5-



carboxamide


A-61
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-
(2-12) pyraclostrobin



(difluoromethyl)-2-methyl-1,3-thiazole-5-



carboxamide









In addition to a carboxamide of the formula (I) (group 1), the active compound combinations B also comprise a triazole of the formula (III) (group 3)




in which Q, m, R16, R17, A4, A5, R18 and R19 are as defined above.

Preference is given to active compound combinations B in which the triazole of the formula (III) (group 3) is selected from the list below:

    (3-1) azaconazole
    (3-2) etaconazole
    (3-3) propiconazole
    (3-4) difenoconazole
    (3-5) bromuconazole
    (3-6) cyproconazole
    (3-7) hexaconazole
    (3-8) penconazole
    (3-9) myclobutanil
    (3-10) tetraconazole
    (3-11) flutriafol
    (3-12) epoxiconazole
    (3-13) flusilazole
    (3-14) simeconazole
    (3-15) prothioconazole
    (3-16) fenbuconazole
    (3-17) tebuconazole
    (3-18) ipconazole
    (3-19) metconazole
    (3-20) triticonazole
    (3-21) bitertanol
    (3-22) triadimenol
    (3-23) triadimefon
    (3-24) fluquinconazole
    (3-25) quinconazole


Particular preference is given to active compound combinations B in which the triazole of the formula (III) (group 3) is selected from the list below:

    (3-3) propiconazole
    (3-4) difenoconazole
    (3-6) cyproconazole
    (3-7) hexaconazole
    (3-15) prothioconazole
    (3-17) tebuconazole
    (3-21) bitertanol
    (3-19) metconazole
    (3-22) triadimenol
    (3-24) fluquinconazole


Emphasis is given to the active compound combinations B listed in Table 2 below:







TABLE 2







Active compound combinations B











Triazole of the


No.
Carboxamide of the formula (I)
formula (III)





B-1
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(3-3) propiconazole



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


B-2
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(3-6) cyproconazole



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


B-3
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(3-15) prothioconazole



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


B-4
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(3-17) tebuconazole



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


B-5
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(3-21) bitertanol



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


B-6
(1-2) 3-(difluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)-
(3-3) propiconazole



methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4-



carboxamide


B-7
(1-2) 3-(difluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)-
(3-6) cyproconazole



methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4-



carboxamide


B-8
(1-2) 3-(difluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)-
(3-15) prothioconazole



methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4-



carboxamide


B-9
(1-2) 3-(difluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)-
(3-17) tebuconazole



methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4-



carboxamide


B-10
(1-2) 3-(difluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)-
(3-21) bitertanol



methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4-



carboxamide


B-11
(1-3) 3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)-
(3-3) propiconazole



methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4-



carboxamide


B-12
(1-3) 3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)-
(3-6) cyproconazole



methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4-



carboxamide


B-13
(1-3) 3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)-
(3-15) prothioconazole



methyl-]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4-



carboxamide


B-14
(1-3) 3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)-
(3-17) tebuconazole



methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4-



carboxamide


B-15
(1-3) 3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)-
(3-21) bitertanol



methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4-



carboxamide


B-16
(1-4) N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro-1,3-
(3-3) propiconazole



dimethyl-1H-pyrazole-4-carboxamide


B-17
(1-4) N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro-1,3-
(3-6) cyproconazole



dimethyl-1H-pyrazole-4-carboxamide


B-18
(1-4) N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro-1,3-
(3-15) prothioconazole



dimethyl-1H-pyrazole-4-carboxamide


B-19
(1-4) N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro-1,3-
(3-17) tebuconazole



dimethyl-1H-pyrazole-4-carboxamide


B-20
(1-4) N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro-1,3-
(3-21) bitertanol



dimethyl-1H-pyrazole-4-carboxamide


B-21
(1-5) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-methyl-
(3-3) propiconazole



4-(trifluoromethyl)-1,3-thiazole-5-carboxamide


B-22
(1-5) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-methyl-
(3-6) cyproconazole



4-(trifluoromethyl)-1,3-thiazoie-5-carboxamide


B-23
(1-5) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-methyl-
(3-15) prothioconazole



4-(trifluoromethyl)-1,3-thiazole-5-carboxamide


B-24
(1-5) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-methyl-
(3-17) tebuconazole



4-(trifluoromethyl)-1,3-thiazole-5-carboxamide


B-25
(1-5) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-methyl-
(3-21) bitertanol



4-(trifluoromethyl)-1,3-thiazole-5-carboxamide


B-26
(1-6) N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-3) propiconazole



2-methyl-1,3-thiazole-5-carboxamide


B-27
(1-6) N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-6) cyproconazole



2-methyl-1,3-thiazole-5-carboxamide


B-28
(1-6) N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-15) prothioconazole



2-methyl-1,3-thiazole-5-carboxamide


B-29
(1-6) N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-17) tebuconazole



2-methyl-1,3-thiazole-5-carboxamide


B-30
(1-6) N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-21) bitertanol



2-methyl-1,3-thiazole-5-carboxamide


B-31
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-3) propiconazole



2-methyl-1,3-thiazole-5-carboxamide


B-32
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-6) cyproconazole



2-methyl-1,3-thiazole-5-carboxamide


B-33
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-15) prothioconazole



2-methyl-1,3-thiazole-5-carboxamide


B-34
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-17) tebuconazole



2-methyl-1,3-thiazole-5-carboxamide


B-35
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-21) bitertanol



2-methyl-1,3-thiazole-5-carboxamide


B-36
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(3-3) propiconazole



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


B-37
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(3-6) cyproconazole



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


B-38
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(3-15) prothioconazole



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


B-39
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(3-17) tebuconazole



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


B-40
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(3-21) bitertanol



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


B-41
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(3-4) difenoconazole



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


B-42
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(3-7) hexaconazole



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


B-43
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(3-19) metconazole



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


B-44
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(3-22) triadimenol



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


B-45
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(3-24) fluquinconazole



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


B-46
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-4) difenoconazole



2-methyl-1,3-thiazole-5-carboxamide


B-47
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-7) hexaconazole



2-methyl-1,3-thiazole-5-carboxamide


B-48
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-19) metconazole



2-methyl-1,3-thiazole-5-carboxamide


B-49
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-22) triadimenol



2-methyl-1,3-thiazole-5-carboxamide


B-50
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-24) fluquinconazole



2-methyl-1,3-thiazole-5-carboxamide


B-51
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(3-4) difenoconazole



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


B-52
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(3-7) hexaconazole



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


B-53
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(3-19) metconazole



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


B-54
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(3-22) triadimenol



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


B-55
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(3-24) fluquinconazole



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


B-56
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-4) difenoconazole



2-methyl-1,3-thiazole-5-carboxamide


B-57
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-7) hexaconazole



2-methyl-1,3-thiazole-5-carboxamide


B-58
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-19) metconazole



2-methyl-1,3-thiazole-5-carboxamide


B-59
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-22) triadimenol



2-methyl-1,3-thiazole-5-carboxamide


B-60
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-24) fluquinconazole



2-methyl-1,3-thiazole-5-carboxamide


B-61
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-3) propiconazole



2-methyl-1,3-thiazole-5-carboxamide


B-62
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-6) cyproconazole



2-methyl-1,3-thiazole-5-carboxamide


B-63
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-15) prothioconazole



2-methyl-1,3-thiazole-5-carboxamide


B-64
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-17) tebuconazole



2-methyl-1,3-thiazole-5-carboxamide


B-65
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(3-21) bitertanol



2-methyl-1,3-thiazole-5-carboxamide









In addition to a carboxamide of the formula (I) (group 1), the active compound combinations C also comprise a sulphenamide of the formula (IV) (group 4)




in which R22 is as defined above.

Preference is given to active compound combinations C in which the sulphenamide of the (formula (IV) (group 4) is selected from the following list:

    (4-1) dichlofluanid
    (4-2) tolylfluanid


Emphasis is given to the active compound combinations C listed in Table 3 below:







TABLE 3







Active compound combinations C











Sulphenamide of the


No.
Carboxamide of the formula (I)
formula (IV)





C-1
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(4-1) dichlofluanid



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


C-2
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(4-2) tolylfluanid



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


C-3
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(4-1) dichlofluanid



2-methyl-1,3-thiazole-5-carboxamide


C-4
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(4-2) tolylfluanid



2-methyl-1,3-thiazole-5-carboxamide


C-5
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(4-1) dichlofluanid



1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide


C-6
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(4-2) tolylfluanid



1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide


C-7
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(4-1) dichlofluanid



2-methyl-1,3-thiazole-5-carboxamide


C-8
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(4-2) tolyfluanid



2-methyl-1,3-thiazole-5-carboxamide









In addition to a carboxamide of the formula (I) (group 1), the active compound combinations D also comprise a valinamide (group 5) selected from

    (5-1) iprovalicarb
    (5-2) N1-[2-(4-{[3-(4-chlorophenyl)-2-propynyl]oxy}-3-methoxyphenyl)ethyl]-N2-(methylsulphonyl)-D-valinamide
    (5-3) benthiavalicarb


Preference is given to active compound combinations D in which the valinamide (group 5) is selected from the following list:

    (5-1) iprovalicarb
    (5-3) benthiavalicarb


Emphasis is given to the active compound combinations D listed in Table 4 below:







TABLE 4







Active compound combinations D









No.
Carboxamide of the formula (I)
Valinamide





D-1
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-
(5-1) iprovalicarb



1-methyl-1H-pyrazole-4-carboxamide


D-2
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-
(5-2) benthiavalicarb



1-methyl-1H-pyrazole-4-carboxamide


D-3
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-
(5-1) iprovalicarb



thiazole-5-carboxamide


D-4
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-
(5-2) benthiavalicarb



thiazole-5-carboxamide


D-5
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(5-1) iprovalicarb



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


D-6
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(5-2) benthiavalicarb



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


D-7
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-
(5-1) iprovalicarb



methyl-1,3-thiazole-5-carboxamide


D-8
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-
(5-2) benthiavalicarb



methyl-1,3-thiazole-5-carboxamide









In addition to a carboxamide of the formula (I) (group 1), the active compound combinations E also comprise a carboxamide of the formula (VI) (group 6)




in which X, Y and Z are as defined above.

Preference is given to active compound combinations E in which the carboxamide of the formula (V) (group 6) is selected from the list below:

    (6-1) 2-chloro-N-(1,1,3-trimethylindan-4-yl)nicotinamide
    (6-2) boscalid
    (6-3) furametpyr
    (6-4) N-(3-p-tolylthiophen-2-yl)-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide
    (6-5) ethaboxam
    (6-6) fenhexamid
    (6-7) carpropamid
    (6-8) 2-chloro-4-(2-fluoro-2-methylpropionylamino)-N,N-dimethylbenzamide
    (6-9) picobenzamid
    (6-10) zoxamide
    (6-11) 3,4-dichloro-N-(2-cyanophenyl)isothiazole-5-carboxamide
    (6-12) carboxin
    (6-13) tiadinil
    (6-14) penthiopyrad
    (6-15) silthiofam
    (6-16) N-[2-(1,3-dimethylbutyl)phenyl]-1-methyl-4-trifluoromethyl)-1H-pyrrole-3-carboxamide


(Particular preference is given to active compound combinations E in which the carboxamide of the formula (V) (group 6) is selected from the list below:

    (6-2) boscalid
    (6-5) ethaboxam
    (6-6) fenhexamid
    (6-7) carpropamid
    (6-8) 2-chloro-4-(2-fluoro-2-methylpropionylamino)-N,N-dimethylbenzamide
    (6-9) picobenzamid
    (6-10) zoxamide
    (6-11) 3,4-dichloro-N-(2-cyanophenyl)isothiazole-5-carboxamide
    (6-14) penthiopyrad
    (6-16) N-[2-(1,3-dimethylbutyl)phenyl]-1-methyl-4-trifluoromethyl)-1H-pyrrole-3-carboxamide


Very particular preference is given to active compound combinations E in which the carboxamide of the formula (V) (group 6) is selected from the list below:

    (6-2) boscalid
    (6-6) fenhexamid
    (6-7) carpropamid
    (6-9) picobenzamid
    (6-14) penthiopyrad


Emphasis is given to the active compound combinations E listed in Table 5 below:







TABLE 5







Active compound combinations E











Carboxamide of the


No.
Carboxamide of the formula (I)
formula (V)





E-1
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(6-2) boscalid



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


E-2
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(6-6) fenhexamid



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


E-3
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(6-7) carpropamid



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


E-4
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(6-9) picobenzamid



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


E-5
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(6-14) penthiopyrad



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


E-6
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(6-2) boscalid



2-methyl-1,3-thiazole-5-carboxamide


E-7
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(6-6) fenhexamid



2-methyl-1,3-thiazole-5-carboxamide


E-8
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(6-7) carpropamid



2-methyl-1,3-thiazole-5-carboxamide


E-9
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(6-9) picobenzamid



2-methyl-1,3-thiazole-5-carboxamide


E-10
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(6-14) penthiopyrad



2-methyl-1,3-thiazole-5-carboxamide


E-11
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(6-2) boscalid



1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide


E-12
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(6-6) fenhexamid



1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide


E-13
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(6-7) carpropamid



1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide


E-14
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(6-9) picobenzamid



1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide


E-15
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(6-14) penthiopyrad



1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide


E-16
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(6-2) boscalid



2-methyl-1,3-thiazole-5-carboxamide


E-17
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(6-6) fenhexamid



2-methyl-1,3-thiazole-5-carboxamide


E-18
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(6-7) carpropamid



2-methyl-1,3-thiazole-5-carboxamide


E-19
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(6-9) picobenzamid



2-methyl-1,3-thiazole-5-carboxamide


E-20
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(6-14) penthiopyrad



2-methyl-1,3-thiazole-5-carboxamide









In addition to a carboxamide of the formula (I) (group 1), the active compound combinations F also comprise a dithiocarbamate (group 7) selected from

    (7-1) mancozeb
    (7-2) maneb
    (7-3) metiram
    (7-4) propineb
    (7-5) thiram
    (7-6) zineb
    (7-7) ziram


Preference is given to active compound combinations F in which the dithiocarbamate (group 7) is selected from the following list:

    (7-1) mancozeb
    (7-2) maneb
    (7-4) propineb
    (7-5) thiram
    (7-6) zineb


Particular preference is given to active compound combinations F in which the dithiocarbamate (group 7) is selected from the following list:

    (7-1) mancozeb
    (7-4) propineb


Emphasis is given to the active compound combinations F listed in Table 6 below:







TABLE 6







Active compound combinations F









No.
Carboxamide of the formula (I)
Dithiocarbamate





F-1
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-
(7-1) mancozeb



1-methyl-1H-pyrazole-4-carboxamide


F-2
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-
(7-4) propineb



1-methyl-1H-pyrazole-4-carboxamide


F-3
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-
(7-1) mancozeb



thiazole-5-carboxamide


F-4
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-
(7-4) propineb



thiazole-5-carboxamide


F-5
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(7-1) mancozeb



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


F-6
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(7-4) propineb



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


F-7
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)4-(difluoromethyl)-2-
(7-1) mancozeb



methyl-1,3-thiazole-5-carboxamide


F-8
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-
(7-4) propineb



methyl-1,3-thiazole-5-carboxamide









In addition to a carboxamide of the formula (I) (group 1), the active compound combinations G also comprise an acylalanine of the formula (VI) (group 8)




in which * and R26 are as defined above.

Preference is given to active compound combinations G in which the acylalanine of the formula (VI) (group 8) is selected from the following list:

    (8-1) benalaxyl
    (8-2) furalaxyl
    (8-3) metalaxyl
    (8-4) metalaxyl-M
    (8-5) benalaxyl-M


Particular preference is given to active compound combinations G in which the acylalanine of the formula (VI) (group 8) is selected from the following list:

    (8-3) metalaxyl
    (8-4) metalaxyl-M
    (8-5) benalaxyl-M


Emphasis is given to the active compound combinations G listed in Table 7 below:







TABLE 7







Active compound combinations G











Acylalanine of the


No.
Corboxamide of the formula (I)
formula (VI)





G-1
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(8-3) metalaxyl



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


G-2
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(8-4) metalaxyl-M



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


G-3
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(8-5) benalaxyl-M



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


G-4
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(8-3) metalaxyl



2-methyl-1,3-thiazole-5-carboxamide


G-5
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(8-4) metalaxyl-M



2-methyl-1,3-thiazole-5-carboxamide


G-6
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(8-5) benalaxyl-M



2-methyl-1,3-thiazole-5-carboxamide


G-7
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(8-3) metalaxyl



1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide


G-8
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(8-4) metalaxyl-M



1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide


G-9
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-trifluoromethyl)-
(8-5) benalaxyl-M



1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide


G-10
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoro-
(8-3) metalaxyl



methyl)-2-methyl-1,3-thiazole-5-carboxamide


G-11
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoro-
(8-4) metalaxyl-M



methyl)-2-methyl-1,3-thiazole-5-carboxamide


G-12
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoro-
(8-5) benalaxyl-M



methyl)-2-methyl-1,3-thiazole-5-carboxamide









In addition to a carboxamide of the formula (I) (group 1), the active compound combinations H also comprise an anilinopyrimidine (group 9) selected from

    (9-1) cyprodinil
    (9-2) mepanipyrim
    (9-3) pyrimethanil


Emphasis is given to the active compound combinations H listed in Table 8 below:







TABLE 8







Active compound combinations H









No.
Carboxamide of the formula (I)
Anilinopyrimidine





H-1
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(9-1) cyprodinil



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


H-2
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(9-2) mepanipyrim



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


H-3
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(9-3) pyrimethanil



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


H-4
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(9-1) cyprodinil



2-methyl-1,3-thiazole-5-carboxamide


H-5
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(9-2) mepanipyrim



2-methyl-1,3-thiazole-5-carboxamide


H-6
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(9-3) pyrimethanil



2-methyl-1,3-thiazole-5-carboxamide


H-7
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(9-1) cyprodinil



1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide


H-8
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(9-2) mepanipyrim



1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide


H-9
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(9-3) pyrimethanil



1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide


H-10
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoro-
(9-1) cyprodinil



methyl)-2-methyl-1,3-thiazole-5-carboxamide


H-11
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoro-
(9-2) mepanipyrim



methyl)-2-methyl-1,3-thiazole-5-carboxamide


H-12
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoro-
(9-3) pyrimethanil



methyl)-2-methyl-1,3-thiazole-5-carboxamide









In addition to a carboxamide of the formula (I) (group 1), the active compound combinations I also comprise a benzimidazole of the formula (VIII) (group 10)




in which R28, R29, R30 and R31 are as defined above.

Preference is given to active compound combinations I in which the benzimidazole of the formula (VIII) (group 10) is selected form the following list:

    (10-1) 6-chloro-5-[(3,5-dimethylisoxazol-4-yl)sulphonyl]-2,2-difluoro-5H-[1,3]dioxolo[4,5-f]-benzimidazole
    (10-2) benomyl
    (10-3) carbendazim
    (10-4) chlorfenazole
    (10-5) fuberidazole
    (10-6) thiabendazole


Particular preference is given to active compound combinations I in which the benzimidazole of the formula (VIII) (group 10) is:

    (10-3) carbendazim


Emphasis is given to the active compound combinations I listed in Table 9 below:







TABLE 9







Active compound combinations I











Benzimidazole of the


No.
carboxamide of the formula (I)
formula (VIII)





I-1
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(10-3) carbendazim



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


I-2
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-
(10-3) carbendazim



1,3-thiazole-5-carboxamide


I-3
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(10-3) carbendazim



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


I-4
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(10-3) carbendazim



2-methyl-1,3-thiazole-5-carboxamide









In addition to a carboxamide of the formula (I) (group 1), the active compound combinations J also comprise a carbamate (group 11) of the formula (IX)




in which R32 and R33 are as defined above.

Preference is given to active compound combinations J in which the carbamate (group 11) is selected from the following list:

    (11-1) diethofencarb
    (11-2) propamocarb
    (11-3) propamocarb-hydrochloride
    (11-4) propamocarb-fosetyl


Emphasis is given to the active compound combinations J listed in Table 10 below:







TABLE 10







Active compound combinations J











Carbamate of the


No.
Carboxamide of the formula (I)
formula (IX)





J-1
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(11-2) propamocarb



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


J-2
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(11-3) propamocarb-



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide
hydrochloride


J-3
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(11-4) propamocarb-fosetyl



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


J-4
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(11-2) propamocarb



2-methyl-1,3-thiazole-5-carboxamide


J-5
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(11-3) propamocarb-



2-methyl-1,3-thiazole-5-carboxamide
hydrochloride


J-6
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(11-4) propamocarb-fosetyl



2-methyl-1,3-thiazole-5-carboxamide


J-7
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(11-2) propamocarb



1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide


J-8
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(11-3) propamocarb-



1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide
hydrochloride


J-9
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(11-4) propamocarb-fosetyl



1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide


J-10
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoro-
(11-2) propamocarb



methyl)-2-methyl-1,3-thiazole-5-carboxamide


J-11
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoro-
(11-3) propamocarb-



methyl)-2-methyl-1,3-thiazole-5-carboxamide
hydrochloride


J-12
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoro-
(11-4) propamocarb-fosetyl



methyl)-2-methyl-1,3-thiazole-5-carboxamide









In addition to a carboxamide of the formula (I) (group 1), the active compound combinations K also comprise a dicarboximide (group 12) selected from

    (12-1) captafol
    (12-2) captan
    (12-3) folpet
    (12-4) iprodione
    (12-5) procymidone
    (12-6) vinclozolin


Preference is given to active compound combinations K in which the dicarboximide (group 12) is selected from the following list:

    (12-2) captan
    (12-3) folpet
    (12-4) iprodione


Emphasis is given to the active compound combinations K listed in Table 11 below:







TABLE 11







Active compound combinations K









No.
Carboxamide of the formula (I)
Dicarboximide





K-1
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-
(12-2) captan



1-methyl-1H-pyrazole-4-carboxamide


K-2
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-
(12-3) folpet



1-methyl-1H-pyrazole-4-carboxamide


K-3
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-
(12-4) iprodione



1-methyl-1H-pyrazole-4-carboxamide


K-4
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-
(12-2) captan



thiazole-5-carboxamide


K-5
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-
(12-3) folpet



thiazole-5-carboxamide


K-6
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-
(12-4) iprodione



thiazole-5-carboxamide


K-7
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1.1′-
(12-2) captan



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


K-8
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(12-3) folpet



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


K-9
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(12-4) iprodione



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


K-10
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-
(12-2) captan



methyl-1,3-thiazole-5-carboxamide


K-11
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-
(12-3) folpet



methyl-1,3-thiazole-5-carboxamide


K-12
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-
(12-4) iprodione



methyl-1,3-thiazole-5-carboxamide









In addition to a carboxamide of the formula (I) (group 1), the active compound combinations L also comprise a guanidine (group 13) selected from

    (13-1) dodine
    (13-2) guazatine
    (13-3) iminoctadine triacetate
    (13-4) iminoctadine tris(albesilate)


Preference is given to active compound combinations L in which the guanidine (group 13) is selected from the following list:

    (13-1) dodine
    (13-2) guazatine


Emphasis is given to the active compound combinations L listed in Table 12 below:







TABLE 12







Active compound combinations L









No.
Carboxamide of the formula (I)
Guanidine





L-1
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-
(13-1) dodine



1-methyl-1H-pyrazole-4-carboxamide


L-2
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-
(13-2) guazatine



1-methyl-1H-pyrazole-4-carboxamide


L-3
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-
(13-1) dodine



thiazole-5-carboxamide


L-4
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-
(13-2) guazatine



thiazole-5-carboxamide


L-5
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(13-1) dodine



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


L-6
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(13-2) guazatine



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


L-7
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-
(13-1) dodine



methyl-1,3-thiazole-5-carboxamide


L-8
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-
(13-2) guazatine



methyl-1,3-thiazole-5-carboxamide









In addition to a carboxamide of the formula (I) (group 1), the active compound combinations M also comprise an imidazole (group 14) selected from

    (14-1) cyazofamid
    (14-2) prochloraz
    (14-3) triazoxide
    (14-4) pefurazoate


Preference is given to active compound combinations M in which the imidazole (group 14) is selected from the following list:

    (14-2) prochloraz
    (14-3) triazoxide


Emphasis is given to the active compound combinations M listed in Table 13 below:







TABLE 13







Active compound combinations M









No.
Carboxamide of the formula (I)
Imidazole





M-1
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-
(14-2) prochloraz



1-methyl-1H-pyrazole-4-carboxamide


M-2
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-
(14-3) triazoxide



1-methyl-1H-pyrazole-4-carboxamide


M-3
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-
(14-2) prochloraz



thiazole-5-carboxamide


M-4
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-
(14-3) triazoxide



thiazole-5-carboxamide


M-5
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(14-2) prochloraz



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


M-6
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(14-3) triazoxide



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


M-7
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-
(14-2) prochloraz



methyl-1,3-thiazole-5-carboxamide


M-8
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-
(14-3) triazoxide



methyl-1,3-thiazole-5-carboxamide









In addition to a carboxamide of the formula (I) (group 1), the active compound combinations N also comprise a morpholine (group 15) of the formula (X)




in which R34, R35 and R36 are as defined above.

Preference is given to active compound combinations N in which the morpholine (group 15) of the formula (X) is selected from the following list:

    (15-1) aldimorph
    (15-2) tridemorph
    (15-3) dodemorph
    (15-4) fenpropimorph
    (15-5) dimethomorph


Particular preference is given to active compound combinations N in which the morpholine (group 15) of the formula (X) is selected from the following list:

    (15-4) fenpropimorph
    (15-5) dimethomorph


Emphasis is given to the active compound combinations N listed in Table 14 below:







TABLE 14







Active compound combinations N











Morpholine of the


No.
Carboxamide of the formula (I)
formula (X)





N-1
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(15-4) fenpropimorph



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


N-2
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(15-4) fenpropimorph



2-methyl-1,3-thiazole-5-carboxamide


N-3
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(15-4) fenpropimorph



1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide


N-4
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(15-4) fenpropimorph



2-methyl-1,3-thiazole-5-carboxamide









In addition to a carboxamide of the formula (I) (group 1), the active compound combinations O also comprise a pyrrole (group 16) of the formula (XI)




in which R37, R38 and R39 are as defined above.

Preference is given to active compound combinations O in which the pyrrole (group 16) of the formula (XI) is selected from the following list:

    (16-1) fenpiclonil
    (16-2) fludioxonil
    (16-3) pyrrolnitrin


Particular preference is given to active compound combinations O in which the pyrrole (group 16) of the formula (XI) is selected from the following list:

    (16-2) fludioxonil


Emphasis is given to the active compound combinations 0 listed in Table 15 below:







TABLE 15







Active compound combinations O











Pyrrole of the


No.
Carboxamide of the formula (I)
formula (XI)





O-1
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(16-2) fludioxonil



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


O-2
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-
(16-2) fludioxonil



1,3-thiazole-5-carboxamide


O-3
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(16-2) fludioxonil



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


O-4
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-
(16-2) fludioxonil



methyl-1,3-thiazole-5-carboxamide









In addition to a carboxamide of the formula (I) (group 1), the active compound combinations P also comprise a phosphonate (group 17) selected from

    (17-1) fosetyl-Al
    (17-2) phosphonic acid


Emphasis is given to the active compound combinations P listed in Table 16 below:







TABLE 16







Active compound combinations P









No.
Carboxamide of the formula (I)
Phosphonate





P-1
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(17-1) fosetyl-Al



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


P-2
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-
(17-1) fosetyl-Al



1,3-thiazole-5-carboxamide


P-3
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(17-1) fosetyl-Al



biphenyl-2-yl]-1,3-thiazole-5-carboxamide


P-4
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-
(17-1) fosetyl-Al



methyl-1,3-thiazole-5-carboxamide









In addition to a carboxamide of the formula (I) (group 1), the active compound combinations Q also comprise a fungicide (group 19) selected from

    (19-1) acibenzolar-S-methyl
    (19-2) chlorothalonil
    (19-3) cymoxanil
    (19-4) edifenphos
    (19-5) famoxadone
    (19-6) fluazinam
    (19-7) copper oxychloride
    (19-8) copper hydroxide
    (19-9) oxadixyl
    (19-10) spiroxamine
    (19-11) dithianon
    (19-12) metrafenone
    (19-13) fenamidone
    (19-14) 2,3-dibutyl-6-chlorothieno[2,3-d]pyrimidin-4(3H)one
    (19-15) probenazole
    (19-16) isoprothiolane
    (19-17) kasugamycin
    (19-18) phthalide
    (19-19) ferimzone
    (19-20) tricyclazole
    (19-21) N-({4-[(cyclopropylamino)carbonyl]phenyl}sulphonyl)-2-methoxybenzamide
    (19-22) 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide


Preference is given to active compound combinations Q in which the fungicide (group 19) is selected from the following list:

    (19-1) acibenzolar-S-methyl
    (19-2) chlorothalonil
    (19-3) cymoxanil
    (19-5) famoxadone
    (19-6) fluazinam
    (19-7) copper oxychloride
    (19-9) oxadixyl
    (19-10) spiroxamine
    (19-13) fenamidone
    (19-21) N-({4-[(cyclopropylamino)carbonyl]phenyl}sulphonyl)-2-methoxybenzamide
    (19-22) 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide


Particular preference is given to active compound combinations Q in which the fungicide (group 19) is selected from the following list:

    (19-2) chlorothalonil
    (19-7) copper oxychloride
    (19-10) spiroxamine
    (19-21) N-({4-[(cyclopropylamino)carbonyl]phenyl}sulphonyl)-2-methoxybenzamide
    (19-22) 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide


Emphasis is given to the active compound combinations Q listed in Table 17 below:







TABLE 17







Active compound combinations Q









No.
Carboxamide of the formula (I)
Fungicide





Q-1
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(19-2) chlorothalonil



(difluoromethyl)-1-methyl-1H-pyrazole-4-



carboxamide


Q-2
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(19-7) copper oxychloride



(difluoromethyl)-1-methyl-1H-pyrazole-4-



carboxamide


Q-3
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(19-10) spiroxamine



(difluoromethyl)-1-methyl-1H-pyrazole-4-



carboxamide


Q-4
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(19-21) N-({4-[(cyclopropylamino)-



(difluoromethyl)-1-methyl-1H-pyrazole-4-
carbonyl]phenyl}sulphonyl)-2-



carboxamide
methoxybenzamide


Q-5
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(19-22) 2-(4-chlorophenyl)-N-{2-[3-



(difluoromethyl)-1-methyl-1H-pyrazole-4-
methoxy-4-(prop-2-yn-1-yloxy)phenyl]-



carboxamide
ethyl}-2-(prop-2-yn-1-yloxy)acetamide


Q-6
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(19-2) chlorothalonil



2-methyl-1,3-thiazole-5-carboxamide


Q-7
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(19-7) copper oxychloride



2-methyl-1,3-thiazole-5-carboxamide


Q-8
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(19-10) spiroxamine



2-methyl-1,3-thiazole-5-carboxamide


Q-9
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(19-21) N-({4-[(cyclopropylamino)-



2-methyl-1,3-thiazole-5-carboxamide
carbonyl]phenyl}sulphonyl)-2-




methoxybenzamide


Q-10
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(19-22) 2-(4-chlorophenyl)-N-{2-[3-



2-methyl-1,3-thiazole-5-carboxamide
methoxy-4-(prop-2-yn-1-yloxy)phenyl]-




ethyl}-2-(prop-2-yn-1-yloxy)acetamide


Q-11
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(19-2) chlorothalonil



1,1′-biphenyl-2-yl]-1,3-thiazole-5-



carboxamide


Q-12
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(19-7) copper oxychloride



1,1′-biphenyl-2-yl]-1,3-thiazole-5-



carboxamide


Q-13
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(19-10) spiroxamine



1,1′-biphenyl-2-yl]-1,3-thiazole-5-



carboxamide


Q-14
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(19-21) N-({4-[(cyclopropylamino)-



1,1′-biphenyl-2-yl]-1,3-thiazole-5-
carbonyl]phenyl}sulphonyl)-2-



carboxamide
methoxybenzamide


Q-15
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(19-22) 2-(4-chlorophenyl)-N-{2-[3-



1,1′-biphenyl-2-yl]-1,3-thiazole-5-
methoxy-4-(prop-2-yn-1-yloxy)phenyl]-



carboxamide
ethyl}-2-(prop-2-yn-1-yloxy)acetamide


Q-16
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-
(19-2) chlorothalonil



(difluoromethyl)-2-methyl-1,3-thiazole-5-



carboxamide


Q-17
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-
(19-7) copper oxychloride



(difluoromethyl)-2-methyl-1,3-thiazole-5-



carboxamide


Q-18
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-
(19-10) spiroxamine



(difluoromethyl)-2-methyl-1,3-thiazole-5-



carboxamide


Q-19
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-
(19-21) N-({4-[(cyclopropylamino)-



(difluoromethyl)-2-methyl-1,3-thiazole-5-
carbonyl]phenyl}sulphonyl)-2-



carboxamide
methoxybenzamide


Q-20
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-
(19-22) 2-(4-chlorophenyl)-N-{2-[3-



(difluoromethyl)-2-methyl-1,3-thiazole-5-
methoxy-4-(prop-2-yn-1-yloxy)phenyl]-



carboxamide
ethyl}-2-(prop-2-yn-1-yloxy)acetamide









In addition to a carboxamide of the formula (I) (group 1), the active compound combinations R also comprise a (thio)urea derivative (group 20) selected from

    (20-1) pencycuron
    (20-2) thiophanate-methyl
    (20-3) thiophanate-ethyl


Preference is given to active compound combinations R in which the (thio)urea derivative (group 20) is selected from the following list:

    (20-1) pencycuron
    (20-2) thiophanate-methyl


Emphasis is given to the active compound combinations R listed in Table 18 below:







TABLE 18







Active compound combinations R









No.
Carboxamide of the formula (I)
(Thio)urea derivative





R-1
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(20-1) pencycuron



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide


R-2
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(20-1) pencycuron



2-methyl-1,3-thiazole-5-carboxamide


R-3
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-
(20-1) pencycuron



1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide


R-4
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoro-
(20-1) pencycuron



methyl)-2-methyl-1,3-thiazole-5-carboxamide









In addition to a carboxamide of the formula (I) (group 1), the active compound combinations S also comprise a triazolopyrimidine (group 22) of the formula (XIV)




in which R43, R44, R45, R46, R47, R48, R49 and R50 are as defined above.

Preference is given to active compound combinations S in which the triazolopyrimidine (group 22) of the formula (XIV) is selected from the list below:

    (22-1) 5-chloro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo-[1,5-a]pyrimidine-7-amine
    (22-2) 5-chloro-N-[(1R)-1,2-dimethylpropyl]-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]-(pyrimidine-7-amine
    (22-3) 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]-pyrimidine
    (22-4) 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine


Particular preference is given to active compound combinations S in which the triazolopyrimidine (group 22) of the formula (XIV) is selected from the list below:

    (22-1) 5-chloro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo-[1,5-a]pyrimidine-7-amine
    (22-2) 5-chloro-N-[(1R)-1,2-dimethylpropyl]-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]-pyrimidine-7-amine
    (22-4) 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine


Emphasis is given to the active compound combinations S listed in Table 19 below:







TABLE 19







Active compound combinations S









No.
Carboxamide of the formula (I)
Triazolopyrimidine of the formula (XIV)





S-1
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-
(22-1) 5-chloro-N-[(1S)-2,2,2-trifluoro-1-



biphenyl-2-yl)-3-(difluoromethyl)-1-
methylethyl]-6-(2,4,6-trifluorophenyl)-



methyl-1H-pyrazole-4-carboxamide
[1,2,4]triazolo[1,5-a]pyrimidine-7-amine


S-2
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-
(22-2) 5-chloro-N-[(1R)-1,2-dimethylpropyl]-6-



biphenyl-2-yl)-3-(difluoromethyl)-1-
(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]-



methyl-1H-pyrazole-4-carboxamide
pyrimidine-7-amine


S-3
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-
(22-4) 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-



biphenyl-2-yl)-3-(difluoromethyl)-1-
methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine



methyl-1H-pyrazole-4-carboxamide


S-4
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-
(22-1) 5-chloro-N-[(1S)-2,2,2-trifluoro-1-



(difluoromethyl)-2-methyl-1,3-thiazole-5-
methylethyl]-6-(2,4,6-trifluorophenyl)-



carboxamide
[1,2,4]triazolo[1,5-a]pyrimidine-7-amine


S-5
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-
(22-2) 5-chloro-N-[(1R)-1,2-dimethylpropyl]-6-



(difluoromethyl)-2-methyl-1,3-thiazole-5-
(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]-



carboxamide
pyrimidine-7-amine


S-6
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-
(22-4) 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-



(difluoromethyl)-2-methyl-1,3-thiazole-5-
methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine



carboxamide


S-7
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-
(22-1) 5-chloro-N-[(1S)-2,2,2-trifluoro-1-



(trifluoromethyl)-1,1′-biphenyl-2-yl]-1,3-
methylethyl]-6-(2,4,6-trifluorophenyl)-



thiazole-5-carboxamide
[1,2,4]triazolo[1,5-a]pyrimidine-7-amine


S-8
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-
(22-2) 5-chloro-N-[(1R)-1,2-dimethylpropyl]-6-



(trifluoromethyl)-1,1′-biphenyl-2-yl]-1,3-
(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]-



thiazole-5-carboxamide
pyrimidine-7-amine


S-9
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-
(22-4) 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-



(trifluoromethyl)-1,1′-biphenyl-2-yl]-1,3-
methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine



thiazole-5-carboxamide


S-10
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-
(22-1) 5-chloro-N-[(1S)-2,2,2-trifluoro-1-



yl)-4-(difluoromethyl)-2-methyl-1,3-
methylethyl]-6-(2,4,6-trifluorophenyl)-



thiazole-5-carboxamide
[1,2,4]triazolo[1,5-a]pyrimidine-7-amine


S-11
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-
(22-2) 5-chloro-N-[(1R)-1,2-dimethylpropyl]-6-



yl)-4-(difluoromethyl)-2-methyl-1,3-
(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]-



thiazole-5-carboxamide
pyrimidine-7-amine


S-12
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-
(22-4) 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-



yl)-4-(difluoromethyl)-2-methyl-1,3-
methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine



thiazole-5-carboxamide









In addition to a carboxamide of the formula (I) (group 1), the active compound combinations T also comprise an iodochromone (group 23) of the formula (XV)




in which R51 and R52 are as defined above.

Preference is given to active compound combinations T in which the iodochromone (group 23) of the formula (XV) is selected from the following list:

    (23-1) 2-butoxy-6-iodo-3-propylbenzopyran-4-one
    (23-2) 2-ethoxy-6-iodo-3-propylbenzopyran-4-one
    (23-3) 6-iodo-2-propoxy-3-propylbenzopyran-4-one
    (23-4) 2-but-2-ynyloxy-6-iodo-3-propylbenzopyran-4-one
    (23-5) 6-iodo-2-(1-methylbutoxy)-3-propylbenzopyran-4-one
    (23-6) 2-but-3-enyloxy-6-iodobenzopyran-4-one
    (23-7) 3-butyl-iodo-2-isopropoxybenzopyran-4-one


Particular preference is given to active compound combinations T in which the iodochromone (group 23) of the formula (XV) is selected from the following list:

    (23-1) 2-butoxy-6-iodo-3-propylbenzopyran-4-one
    (23-2) 2-ethoxy-6-iodo-3-propylbenzopyran-4-one


Emphasis is given to the active compound combinations T listed in Table 20 below:







TABLE 20







Active compound combinations T











Iodochromone of the


No.
Carboxamide of the formula (I)
formula (XV)





T-1
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(23-1) 2-butoxy-6-iodo-3-



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide
propylbenzopyran-4-one


T-2
(1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-
(23-2) 2-ethoxy-6-iodo-3-



(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide
propylbenzopyran-4-one


T-3
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(23-1) 2-butoxy-6-iodo-3-



2-methyl-1,3-thiazole-5-carboxamide
propylbenzopyran-4-one


T-4
(1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-
(23-2) 2-ethoxy-6-iodo-3-



2-methyl-1,3-thiazole-5-carboxamide
propylbenzopyran-4-one


T-5
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(23-1) 2-butoxy-6-iodo-3-



biphenyl-2-yl]-1,3-thiazole-5-carboxamide
propylbenzopyran-4-one


T-6
(1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-
(23-2) 2-ethoxy-6-iodo-3-



biphenyl-2-yl]-1,3-thiazole-5-carboxamide
propylbenzopyran-4-one


T-7
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoro-
(23-1) 2-butoxy-6-iodo-3-



methyl)-2-methyl-1,3-thiazole-5-carboxamide
propylbenzopyran-4-one


T-8
(1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoro-
(23-2) 2-ethoxy-6-iodo-3-



methyl)-2-methyl-1,3-thiazole-5-carboxamide
propylbenzopyran-4-one









In addition to an active compound of the formula (I), the active compound combinations according to the invention comprise at least one active compound from the compounds of groups (2) to (23). In addition, they may also comprise further fungicidally active additives.
If the active compounds in the active compound combinations according to the invention are present in certain weight ratios, the synergistic effect is particularly pronounced. However, the weight ratios of the active compounds in the active compound combinations can be varied within a relatively wide range. In general, the combinations according to the invention comprise active compounds of the formula (I) and a mixing partner from one of the groups (2) to (23) in the mixing ratios listed in an exemplary manner in Table 21 below.
The mixing ratios are based on ratios by weight. The ratio is to be understood as active compound of the formula (I): mixing partner.







TABLE 21







Mixing ratios











Particularly



Preferred
preferred


Mixing partner
mixing ratio
mixing ratio





Group (2): strobilurins
50:1 to 1:50
10:1 to 1:20


Group (3): triazoles except for (3-15)
50:1 to 1:50
20:1 to 1:20


(3-15): prothioconazole
50:1 to 1:50
10:1 to 1:20


Group (4): sulphenamides
 1:1 to 1:150
 1:1 to 1:100


Group (5): valinamides
50:1 to 1:50
10:1 to 1:20


Group (6): carboxamides
50:1 to 1:50
20:1 to 1:20


Group (7): dithiocarbamates
 1:1 to 1:150
 1:1 to 1:100


Group (8): acylalanines
 10:1 to 1:150
 5:1 to 1:100


Group (9): anilinopyrimidines
 5:1 to 1:50
 1:1 to 1:20


Group (10): benzimidazoles
10:1 to 1:50
 5:1 to 1:20


Group (11): carbamates except for
 1:1 to 1:150
 1:1 to 1:100


(11-1)


(11-1): diethofencarb
50:1 to 1:50
10:1 to 1:20


Group (12): (12-1)/(12-2)/(12-3)
 1:1 to 1:150
 1:5 to 1:100


Group (12): (12-4)/(12-5)/(12-6)
 5:1 to 1:50
 1:1 to 1:20


Group (13): guanidines
100:1 to 1:150
 20:1 to 1:100


Group (14): imidazoles
50:1 to 1:50
10:1 to 1:20


Group (15): morpholines
50:1 to 1:50
10:1 to 1:20


Group (16): pyrroles
50:1 to 1:50
10:1 to 1:20


Group (17): phosphonates
 10:1 to 1:150
 1:1 to 1:100


Group (18): phenylethanamides
50:1 to 1:50
10:1 to 1:20


(19-1): acibenzolar-S-methyl
50:1 to 1:50
20:1 to 1:20


(19-2): chlorothalonil
 1:1 to 1:150
 1:1 to 1:100


(19-3): cymoxanil
10:1 to 1:50
 5:1 to 1:20


(19-4): edifenphos
10:1 to 1:50
 5:1 to 1:20


(19-5): famoxadone
50:1 to 1:50
10:1 to 1:20


(19-6): fluazinam
50:1 to 1:50
10:1 to 1:20


(19-7): copper oxychloride
 1:1 to 1:150
 1:5 to 1:100


(19-8): copper hydroxide
 1:1 to 1:150
 1:5 to 1:100


(19-9): oxadixyl
 10:1 to 1:150
 5:1 to 1:100


(19-10): spiroxamine
50:1 to 1:50
10:1 to 1:20


(19-11) dithianon
50:1 to 1:50
10:1 to 1:20


(19-12) metrafenone
50:1 to 1:50
10:1 to 1:20


(19-13) fenamidone
50:1 to 1:50
10:1 to 1:20


(19-14): 2,3-dibutyl-6-chlorothieno-
50:1 to 1:50
10:1 to 1:20


[2,3-d]pyrimidin-4(3H)one


(19-15): probenazole
 10:1 to 1:150
 5:1 to 1:100


(19-16): isoprothiolane
 10:1 to 1:150
 5:1 to 1:100


(19-17): kasugamycin
50:1 to 1:50
10:1 to 1:20


(19-18): phthalide
 10:1 to 1:150
 5:1 to 1:100


(19-19): ferimzone
50:1 to 1:50
10:1 to 1:20


(19-20): tricyclazole
50:1 to 1:50
10:1 to 1:20


(19-21): N-({4-[(cyclopropylamino)-
 10:1 to 1:150
 5:1 to 1:100


carbonyl]phenyl}sulphonyl)-2-


methoxybenzamide


(19-22) 2-(4-chlorophenyl)-N-{2-[3-
50:1 to 1:50
10:1 to 1:20


methoxy-4-(prop-2-yn-1-yloxy)-


phenyl]ethyl}-2-(prop-2-yn-1-


yloxy)acetamide


Group (20): (thio)urea derivatives
50:1 to 1:50
10:1 to 1:20


Group (21): amides
50:1 to 1:50
10:1 to 1:20


Group (22): triazolopyrimidines
50:1 to 1:50
10:1 to 1:20


Group (23): iodochromones
50:1 to 1:50
10:1 to 1:20









In each case, the mixing ratio is to be chosen such that a synergistic mixture is obtained. The mixing ratios between the compound of the formula (I) and a compound of one of the groups (2) to (23) may also vary between the individual compounds of a group.
The active compound combinations according to the invention have very good fungicidal properties and are suitable for controlling phytopathogenic fungi, such as Plasmodiophoromycetes, Oomycetes, Chytridiomycetes, Zygomycetes, Ascomycetes, Basidiomycetes, Deuteromycetes, etc.
The active compound combinations according to the invention are particularly suitable for controlling Erysiphe graminis, Pyrenophora teres and Leptosphaeria nodorum. 
Some pathogens causing fungal diseases which come under the generic names listed above may be mentioned by way of example, but not by way of limitation:
Pythium species, such as, for example, Pythium ultimum; Phytophthora species, such as, for example, Phytophthora infestans; Pseudoperonospora species, such as, for example, Pseudoperonospora humuli or Pseudoperonospora cubensis; Plasmopara species, such as, for example, Plasmopara viticola; Bremia species, such as, for example, Bremia lactucae; Peronospora species, such as, for example, Peronospora pisi or P. brassicae; Erysiphe species, such as, for example, Erysiphe graminis; Sphaerotheca species, such as, for example, Sphaerotheca fuliginea; Podosphaera species, such as, for example, Podosphaera leucoticha; Venturia species, such as, for example, Venturia inaequalis; Pyrenophora species, such as, for example, Pyrenophora teres or P. graminea (conidia form: Drechslera, syn: Helminthosporium); Cochliobolus species, such as, for example, Cochliobolus sativus (conidia form: Drechslera, syn: Helminthosporium); Uromyces species, such as, for example, Uromyces appendiculatus; Puccinia species, such as, for example, Puccinia recondita; Sclerotinia species, such as, for example, Sclerotinia sclerotiorum; Tilletia species, such as, for example, Tilletia caries; Ustilago species, such as, for example, Ustilago nuda or Ustilago avenae; Pellicularia species, such as, for example, Pellicularia sasakii; Pyricularia species, such as, for example, Pyricularia oryzae; Fusarium species, such as, for example, Fusarium culmorum; Botrytis species, such as, for example, Botrytis cinerea; Septoria species, such as, for example, Septoria nodorum; Leptosphaeria species, such as, for example, Leptosphaeria nodorum; Cercospora species, such as, for example, Cercospora canescens; Altemaria species, such as, for example, Alternaria brassicae; Pseudocercosporella species, such as, for example, Pseudocercosporella herpotrichoides, Rhizoctonia species, such as, for example, Rhizoctonia solani. 
The fact that the active compound combinations are well tolerated by plants at the concentrations required for controlling plant diseases permits a treatment of entire plants (above-ground parts of plants and roots), of propagation stock and seed, and of the soil. The active compound combinations according to the invention can be used for foliar application or else as seed dressings.
The active compound combinations according to the invention are also suitable for increasing the yield of crops. In addition, they show reduced toxicity and are well tolerated by plants.
According to the invention, it is possible to treat all plants and parts of plants. Plants are to be understood here as meaning all plants and plant populations, such as desired and undesired wild plants or crop plants (including naturally occurring crop plants). Crop plants can be plants which can be obtained by conventional breeding and optimization methods or by biotechnological and genetic engineering methods or combinations of these methods, including the transgenic plants and including plant cultivars which can or cannot be protected by plant breeders' certificates. Parts of plants are to be understood as meaning all above-ground and below-ground parts and organs of plants, such as shoot, leaf, flower and root, examples which may be mentioned being leaves, needles, stems, trunks, flowers, fruit bodies, fruits and seeds and also roots, tubers and rhizomes. Parts of plants also include harvested material and vegetative and generative propagation material, for example seedlings, tubers, rhizomes, cuttings and seeds.
The treatment of the plants and parts of plants according to the invention with the active compounds is carried out directly or by action on their environment, habitat or storage area according to customary treatment methods, for example by dipping, spraying, evaporating, atomizing, broadcasting, brushing-on and, in the case of propagation material, in particular in the case of seeds, furthermore by one- or multilayer coating.
As already mentioned above, it is possible to treat all plants and their parts according to the invention. In a preferred embodiment, wild plant species and plant cultivars, or those obtained by conventional biological breeding, such as crossing or protoplast fusion, and parts thereof, are treated. In a further preferred embodiment, transgenic plants and plant cultivars obtained by genetic engineering, if appropriate in combination with conventional methods (genetically modified organisms), and parts thereof, are treated. The term “parts” or “parts of plants” or “plant parts” has been explained above.
Particularly preferably, plants of the plant cultivars which are in each case commercially available or in use are treated according to the invention.
Depending on the plant species or plant cultivars, their location and growth conditions (soils, climate, vegetation period, diet), the treatment according to the invention may also result in superadditive (“synergistic”) effects. Thus, for example, reduced application rates and/or a widening of the activity spectrum and/or an increase in the activity of the substances and compositions which can be used according to the invention, better plant growth, increased tolerance to high or low temperatures, increased tolerance to drought or to water or soil salt content, increased flowering performance, easier harvesting, accelerated maturation, higher harvest yields, better quality and/or a higher nutritional value of the harvested products, better storage stability and/or processability of the harvested products are possible which exceed the effects which were actually to be expected.
The transgenic plants or plant cultivars (i.e. those obtained by genetic engineering) which are preferably to be treated according to the invention include all plants which, in the genetic modification, received genetic material which imparted particularly advantageous useful properties (“traits”) to these plants. Examples of such properties are better plant growth, increased tolerance to high or low temperatures, increased tolerance to drought or to water or soil salt content, increased flowering performance, easier harvesting, accelerated maturation, higher harvest yields, better quality and/or a higher nutritional value of the harvested products, better storage stability and/or processability of the harvested products. Further and particularly emphasized examples of such properties are a better defence of the plants against animal and microbial pests, such as against insects, mites, phytopathogenic fungi, bacteria and/or viruses, and also increased tolerance of the plants to certain herbicidally active compounds. Examples of transgenic plants which may be mentioned are the important crop plants, such as cereals (wheat, rice), maize, soya beans, potatoes, cotton, oilseed rape and also fruit plants (with the fruits apples, pears, citrus fruits and grapes), and particular emphasis is given to maize, soya beans, potatoes, cotton and oilseed rape. Traits that are emphasized in particular are increased defence of the plants against insects, by toxins formed in the plants, in particular those formed in the plants by the genetic material from Bacillus thuringiensis (for example by the genes CryIA(a), CryIA(b), CryIA(c), CryIIA, CryIIIA, CryIIIB2, Cry9c, Cry2Ab, Cry3Bb and CryIF and also combinations thereof) (hereinbelow referred to as “Bt plants”). Traits that are furthermore particularly emphasized are the increased tolerance of the plants to certain herbicidally active compounds, for example imidazolinones, sulphonylureas, glyphosates or phosphinotricin (for example the “PAT” gene). The genes which impart the desired traits in question can also be present in combinations with one another in the transgenic plants. Examples of “Bt plants” which may be mentioned are maize varieties, cotton varieties, soya bean varieties and potato varieties which are sold under the trade names YIELD GARD® (for example maize, cotton, soya bean), KnockOut® (for example maize), StarLink® (for example maize), Bollgard® (cotton), Nucoton® (cotton) and NewLeaf® (potato). Examples of herbicide-tolerant plants which may be mentioned are maize varieties, cotton varieties and soya bean varieties which are sold under the trade names Roundup Ready® (tolerance to glyphosates, for example maize, cotton, soya bean), Liberty Link® (tolerance to phosphinotricin, for example oilseed rape), IMI® (tolerance to imidazolinones) and STS® (tolerance to sulphonylureas, for example maize). Herbicide-resistant plants (plants bred in a conventional manner for herbicide tolerance) which may be mentioned also include the varieties sold under the name Clearfield® (for example maize). Of course, these statements also apply to plant cultivars which have these genetic traits or genetic traits still to be developed, and which will be developed and/or marketed in the future.
Depending on their particular physical and/or chemical properties, the active compound combinations according to the invention can be converted into the customary formulations, such as solutions, emulsions, suspensions, powders, dusts, foams, pastes, soluble powders, granules, aerosols, suspoemulsion concentrates, natural and synthetic substances impregnated with active compound and microencapsulations in polymeric substances and in coating compositions for seeds, and ULV cool and warm fogging formulations.
These formulations are produced in a known manner, for example by mixing the active compounds or active compound combinations with extenders, that is liquid solvents, liquefied gases under pressure, and/or solid carriers, optionally with the use of surfactants, that is emulsifiers and/or dispersants, and/or foam formers.
If the extender used is water, it is also possible to employ, for example, organic solvents as auxiliary solvents. Essentially, suitable liquid solvents are: aromatics such as xylene, toluene or alkylnaphthalenes, chlorinated aromatics or chlorinated aliphatic hydrocarbons such as chlorobenzenes, chloroethylenes or methylene chloride, aliphatic hydrocarbons such as cyclohexane or paraffins, for example petroleum fractions, mineral and vegetable oils, alcohols such as butanol or glycol and their ethers and esters, ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone or cyclohexanone, strongly polar solvents such as dimethylformamide and dimethyl sulphoxide, or else water.
Liquefied gaseous extenders or carriers are to be understood as meaning liquids which are gaseous at standard temperature and under atmospheric pressure, for example aerosol propellants such as butane, propane, nitrogen and carbon dioxide.
Suitable solid carriers are: for example ammonium salts, ground natural minerals such as kaolins, clays, talc, chalk, quartz, attapulgite, montmorillonite or diatomaceous earth, and ground synthetic minerals such as finely divided silica, alumina and silicates. Suitable solid carriers for granules are: for example crushed and fractionated natural rocks such as calcite, marble, pumice, sepiolite and dolomite, or else synthetic granules of inorganic and organic meals, and granules of organic material such as sawdust, coconut shells, maize cobs and tobacco stalks. Suitable emulsifiers and/or foam formers are: for example nonionic and anionic emulsifiers, such as polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, for example alkylaryl polyglycol ethers, alkylsulphonates, alkyl sulphates, arylsulphonates, or else protein hydrolysates. Suitable dispersants are: for example lignosulphite waste liquors and methylcellulose.
Tackifiers such as carboxymethylcellulose, natural and synthetic polymers in the form of powders, granules or latices, such as gum arabic, polyvinyl alcohol and polyvinyl acetate, or else natural phospholipids such as cephalins and lecithins and synthetic phospholipids can be used in the formulations. Other possible additives are mineral and vegetable oils.
It is possible to use colorants such as inorganic pigments, for example iron oxide, titanium oxide and Prussian Blue, and organic dyestuffs such as alizarin dyestuffs, azo dyestuffs and metal phthalocyanine dyestuffs, and trace nutrients such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc.
The active compound content of the use forms prepared from the commercial formulations may be varied within wide ranges. The concentration of active compound of the use forms for controlling animal pests, such as insects and acarids, may be from 0.0000001 to 95% by weight of active compound and is preferably from 0.0001 to 1% by weight. Application is in a customary manner adapted to the use forms.
The formulations for controlling unwanted phytopathogenic fungi generally comprise between 0.1 and 95% by weight of active compounds, preferably between 0.5 and 90%.
The active compound combinations according to the invention can be used as such, in the form of their formulations or as the use forms prepared therefrom, such as ready-to-use solutions, emulsifiable concentrates, emulsions, suspensions, wettable powders, soluble powders, dusts and granules. They are used in a customary manner, for example by watering (drenching), drip irrigation, spraying, atomizing, broadcasting, dusting, foaming, spreading-on, and as a powder for dry seed treatment, a solution for seed treatment, a water-soluble powder for seed treatment, a water-soluble powder for slurry treatment, or by encrusting.
The active compound combinations according to the invention can, in commercial formulations and in the use forms prepared from these formulations, be present as a mixture with other active compounds, such as insecticides, attractants, sterilants, bactericides, acaricides, nematicides, fungicides, growth regulators or herbicides.
When using the active compound combinations according to the invention, the application rates can be varied within a relatively wide range, depending on the kind of application. In the treatment of parts of plants, the application rates of active compound combinations are generally between 0.1 and 10 000 g/ha, preferably between 10 and 1000 g/ha. In the treatment of seeds, the application rates of active compound combination are generally between 0.001 and 50 g per kilogram of seed, preferably between 0.01 and 10 g per kilogram of seed. In the treatment of the soil, the application rates of active compound combination are generally between 0.1 and 10 000 g/ha, preferably between 1 and 5000 g/ha.
The active compound combinations can be used as such, in the form of concentrates or in the form of generally customary formulations, such as powders, granules, solutions, suspensions, emulsions or pastes.
The formulations mentioned can be prepared in a manner known per se, for example by mixing the active compounds with at least one solvent or diluent, emulsifier, dispersant and/or binder or fixative, water repellent, if desired desiccants and UV stabilizers, and, if desired, colorants and pigments and other processing auxiliaries.
The good fungicidal action of the active compound combinations according to the invention is demonstrated by the examples below. While the individual active compounds show weaknesses in their fungicidal action, the combinations show an action which exceeds a simple sum of actions.
A synergistic effect in fungicides is always present when the fungicidal action of the active compound combinations exceeds the total of the action of the active compounds when applied individually.
The expected fungicidal action for a given combination of two active compounds can be calculated as follows, according to S. R. Colby (“Calculating Synergistic and Antagonistic Responses of Herbicide Combinations”, Weeds 1967, 15, 20-22):
If

    X is the efficacy when employing active compound A at an application rate of m g/ha,
    Y is the efficacy when employing active compound B at an application rate of n g/ha and
    E is the efficacy when employing active compounds A and B at application rates of m and n g/ha,
    then






  E
  =
  
    X
    +
    Y
    -
    
      
        X
        ×
        Y
      
      100
    
  




Here, the efficacy is determined in %. 0% means an efficacy which corresponds to that of the control, whereas an efficacy of 100% means that no infection is observed.
If the actual fungicidal action exceeds the calculated value, the action of the combination is superadditive, i.e. a synergistic effect is present. In this case, the actually observed efficacy must exceed the value calculated using the above formula for the expected efficacy (E).
The invention is illustrated by the examples below. However, the invention is not limited to the examples.


USE EXAMPLES
In the use examples shown below, in each case mixtures of the carboxamides of the general formula (I) (group 1) below with the mixing partners given in each case (structural formulae see above) were tested.
Carboxamides of the formula (I) used:




Example A
Pyrenophora teres Test (Barley)/Curative
















Solvent:
50 parts by weight of N,N-dimethylacetamide



Emulsifier:
 1 part by weight of alkylaryl polyglycol ether










To produce a suitable preparation of active compound, 1 part by weight of active compound or active compound combination is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.
To test for curative activity, young plants are sprayed with a conidia suspension of Pyrenophora teres. The plants remain in an incubation cabinet at 20° C. and 100% relative atmospheric humidity for 48 hours. The plants are then sprayed with the preparation of active compound at the stated application rate.
The plants are placed in a greenhouse at a temperature of about 20° C. and a relative atmospheric humidity of about 80%.
Evaluation is carried out 12 days after the inoculation. 0% means an efficacy which corresponds to that of the control, whereas an efficacy of 100% means that no infection is observed.
The table below clearly shows that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.







TABLE A







Pyrenophora teres test (barley)/curative










Application




rate of active
Efficacy in %










Active compounds
compound in g/ha
found*
calc.**













(1-1)
25
43



(2-2) fluoxastrobin
25
0


(3-17) tebuconazole
25
29


(1-1) + (2-2) fluoxastrobin (1:1)
25 + 25
71
43


(1-1) + (3-17) tebuconazole (1:1)
25 + 25
71
60





*found = activity found


**calc. = activity calculated using Colby's formula






Example B
Erysiphe Test (Barley)/Protective
















Solvent:
50 parts by weight of N,N-dimethylacetamide



Emulsifier:
 1 part by weight of alkylaryl polyglycol ether










To produce a suitable preparation of active compound, 1 part by weight of active compound or active compound combination is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.
To test for protective activity, young plants are sprayed with the preparation of active compound at the stated application rate. After the spray coating has dried on, the plants are dusted with spores of Erysiphe graminis f.sp. hordei. 
Plants are placed in a greenhouse at a temperature of about 20° C. and a relative atmospheric humidity of about 80% to promote the development of mildew pustules.
Evaluation is carried out 6 days after the inoculation. 0% means an efficacy which corresponds to that of the control, whereas an efficacy of 100% means that no infection is observed.
The table below clearly shows that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.







TABLE B







Erysiphe test (barley)/protective










Application




rate of active



compound
Efficacy in %










Active compounds
in g/ha
found*
calc.**













(1-1)
12.5
0



(2-4) trifloxystrobin
12.5
78


(3-15) prothioconazole
12.5
67


(1-1) + (2-4) trifloxystrobin (1:1)
12.5 + 12.5
94
78


(1-1) + (3-15) prothioconazole (1:1)
12.5 + 12.5
89
67





*found = activity found


**calc. = activity calculated using Colby's formula






Example C
Puccinia Test (Wheat)/Curative
















Solvent:
50 parts by weight of N,N-dimethylacetamide



Emulsifier:
 1 part by weight of alkylaryl polyglycol ether










To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.
To test for curative activity, young plants are sprayed with a conidia suspension of Puccinia recondita. The plants remain in an incubation cabinet at 20° C. and 100% relative atmospheric humidity for 48 hours.
The plants are then sprayed with the preparation of active compound at the stated application rate.
The plants are placed in a greenhouse at a temperature of about 20° C. and a relative atmospheric humidity of about 80% to promote the development of rust pustules.
Evaluation is carried out 8 days after the inoculation. 0% means an efficacy which corresponds to that of the control, whereas an efficacy of 100% means that no infection is observed.
The table below clearly shows that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.







TABLE C







Puccinia test (wheat)/curative










Application




rate of active
Efficacy in %










Active compounds
compound in g/ha
found*
calc.**













(1-1)
62.5
22



(19-10) spiroxamine
62.5
0


(6-14)
62.5
44


(6-11)
62.5
0


(2-11) picoxystrobin
62.5
78


(1-1) + (19-10) spiroxamine (1:1)
62.5 + 62.5
100
22


(1-1) + (6-14) (1:1)
62.5 + 62.5
67
57


(1-1) + (6-11) (1:1)
62.5 + 62.5
44
22


(1-1) + (2-11) picoxystrobin (1:1)
62.5 + 62.5
89
83





*found = activity found


**calc. = activity calculated using Colby's formula






Example D
Gibberella zeae Test (Barley)/Curative
















Solvent:
50 parts by weight of N,N-dimethylacetamide



Emulsifier:
 1 part by weight of alkylaryl polyglycol ether










To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.
To test for curative activity, young plants are sprayed with a conidia suspension of Gibberella zeae. The plants remain in an incubation cabinet at 22° C. and 100% relative atmospheric humidity for 24 hours. The plants are then sprayed with the preparation of active compound at the stated application rate. After the spray coating has dried on, the plants remain in a greenhouse under translucent incubation hoods at a temperature of about 22° C. and a relative atmospheric humidity of about 100%.
Evaluation is carried out 6 days after the inoculation. 0% means an efficacy which corresponds to that of the control, whereas an efficacy of 100% means that no infection is observed.
The table below shows clearly that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.







TABLE D







Gibberella zeae test (barley)/curative










Application




rate of active
Efficacy in %










Active compounds
compound in g/ha
found*
calc.**













(1-1)
62.5
40



(2-12) pyraclostrobin
62.5
80


(3-12) epoxyconazole
62.5
0


(1-1) + (2-12) pyraclostrobin (1:1)
62.5 + 62.5
90
88


(1-1) + (3-12) epoxyconazole (1:1)
62.5 + 62.5
60
40





*found = activity found


**calc. = activity calculated using Colby's formula






Example E
Sphaerotheca fuliginea Test (Cucumber)/Protective
















Solvents:
24.5 parts by weight of acetone




24.5 parts by weight of dimethylacetamide



Emulsifier:
  1 part by weight of alkylaryl polyglycol ether










To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvents and emulsifier, and the concentrate is diluted with water to the desired concentration.
To test for protective activity, young plants are sprayed with the preparation of active compound at the stated application rate. After the spray coating has dried on, the plants are inoculated with an aqueous spore suspension of Sphaerotheca fuliginea. 
The plants are then placed in a greenhouse at about 23° C. and a relative atmospheric humidity of about 70%.
Evaluation is carried out 7 days after the inoculation. 0% means an efficacy which corresponds to that of the control, whereas an efficacy of 100% means that no infection is observed.
The table below clearly shows that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.







TABLE E







Sphaerotheca fuliginea test (cucumber)/protective










Application




rate of active
Efficacy in %










Active compounds
compound in g/ha
found*
calc.**













(1-1)
4
30




2
36



1
16



0.5
0


(1-7)
2
0



1
0



0.5
0


(2-1) azoxystrobin
0.5
20


(2-2) fluoxastrobin
1
0


(2-4) trifloxystrobin
2
10


(2-12) pyraclostrobin
2
0


(3-15) prothioconazole
1
43


(3-17) tebuconazole
1
10


(3-21) bitertanol
1
0


(4-2) tolylfluanid
20
0


(6-6) fenhexamid
20
0


(6-14) penthiopyrad
4
0


(7-1) mancozeb
20
0


(7-4) propineb
20
11


(9-3) pyrimethanil
20
0


(12-4) iprodione
20
0


(19-2) chlorothalonil
20
0


(19-10) spiroxamine
20
0


(22-1)
2
11


(22-2)
1
22


(1-1) + (2-1) azoxystrobin (1:1)
0.5 + 0.5
87
20


(1-7) + (2-1) azoxystrobin (1:1)
0.5 + 0.5
63
20


(1-1) + (2-2) fluoxastrobin (1:1)
1 + 1
95
16


(1-7) + (2-2) fluoxastrobin (1:1)
1 + 1
92
0


(1-1) + (2-4) trifloxystrobin (1:1)
2 + 2
57
42


(1-7) + (2-4) trifloxystrobin (1:1)
2 + 2
93
10


(1-1) + (2-12) pyraclostrobin (1:1)
2 + 2
53
36


(1-1) + (3-15) prothioconazole
1 + 1
70
52


(1:1)


(1-1) + (3-17) tebuconazole (1:1)
1 + 1
90
24


(1-1) + (3-21) bitertanol (1:1)
1 + 1
50
16


(1-1) + (4-2) tolylfluanid (1:10)
 2 + 20
98
36


(1-1) + (6-6) fenhexamid (1:10)
 2 + 20
85
36


(1-1) + (6-14) penthiopyrad (1:1)
4 + 4
82
30


(1-1) + (7-1) mancozeb (1:10)
 2 + 20
93
36


(1-1) + (7-4) propineb (1:10)
 2 + 20
65
43


(1-1) + (9-3) pyrimethanil (1:10)
 2 + 20
96
36


(1-1) + (12-4) iprodione (1:10)
 2 + 20
74
36


(1-1) + (19-2) chlorothalonil (1:10)
 2 + 20
91
36


(1-1) + (19-10) spiroxamine (1:10)
 2 + 20
100
36


(1-1) + (22-1) (1:1)
2 + 2
67
43


(1-1) + (22-2) (1:1)
1 + 1
94
34





*found = activity found


**calc. = activity calculated using Colby's formula






Example F
Alternaria solani Test (Tomato)/Protective
















Solvents:
24.5 parts by weight of acetone




24.5 parts by weight of dimethylacetamide



Emulsifier:
  1 part by weight of alkylaryl polyglycol ether










To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvents and emulsifier, and the concentrate is diluted with water to the desired concentration.
To test for protective activity, young plants are sprayed with the preparation of active compound at the stated application rate. After the spray coating has dried on, the plants are inoculated with an aqueous spore suspension of Alternaria solani. 
The plants are then placed in an incubation cabinet at about 20° C. and 100% relative atmospheric humidity.
Evaluation is carried out 3 days after the inoculation. 0% means an efficacy which corresponds to that of the control, whereas an efficacy of 100% means that no infection is observed.
The table below clearly shows that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.







TABLE F







Alternaria solani test (tomato)/protective










Application




rate of




active compound
Efficacy in %










Active compounds
in g/ha
found*
calc.**













(1-1)
1
61




0.5
42


(1-7)
1
63



0.5
28


(2-3)
0.5
22


(3-3) propiconazole
0.5
3


(5-3) benthiavalicarb
1
5


(8-4) metalaxyl-M
0.5
7


(8-5) benalaxyl-M
0.5
14


(1-7) + (2-3) (1:1)
0.5 + 0.5
67
44


(1-7) + (3-3) propiconazole (1:1)
0.5 + 0.5
56
30


(1-1) + (5-3) benthiavalicarb (1:1)
1 + 1
77
63


(1-1) + (8-4) metalaxyl-M (1:1)
0.5 + 0.5
62
46


(1-1) + (8-5) benalaxyl-M (1:1)
0.5 + 0.5
67
50





*found = activity found


**calc. = activity calculated using Colby's formula






Example G
Phytophthora infestans Test (Tomato)/Protective
















Solvents:
24.5 parts by weight of acetone




24.5 parts by weight of dimethylacetamide



Emulsifier:
  1 part by weight of alkylaryl polyglycol ether










To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvents and emulsifier, and the concentrate is diluted with water to the desired concentration.
To test for protective activity, young plants are sprayed with the preparation of active compound at the stated application rate. After the spray coating has dried on, the plants are inoculated with an aqueous spore suspension of Phytophthora infestans. The plants are then placed in an incubation cabinet at about 20° C. and 100% relative atmospheric humidity.
Evaluation is carried out 3 days after the inoculation. 0% means an efficacy which corresponds to that of the control, whereas an efficacy of 100% means that no infection is observed.
The table below clearly shows that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.







TABLE G







Phytophthora infestans test (tomato)/protective










Application




rate of



active compound
Efficacy in %










Active compounds
in g/ha
found*
calc.**













(1-1)
10
0




5
0



1
0



0.5
0


(4-2) tolylfluanid
10
0


(5-1) iprovalicarb
10
64



5
61


(5-3) benthiavalicarb
0.5
56


(19-13) fenamidone
0.5
41


(1-1) + (4-2) tolylfluanid (1:10)
1 + 10
51
0


(1-1) + (5-1) iprovalicarb (1:1)
10 + 10
88
64



5 + 5
77
61


(1-1) + (5-3) benthiavalicarb (1:1)
0.5 + 0.5
73
56


(1-1) + (19-13) fenamidone (1:1)
0.5 + 0.5
51
41





*found = activity found


**calc. = activity calculated using Colby's formula






Example H
Botrytis cinerea Test (Bean)/Protective
















Solvents:
24.5 parts by weight of acetone




24.5 parts by weight of dimethylacetamide



Emulsifier:
  1 part by weight of alkylaryl polyglycol ether










To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvents and emulsifier, and the concentrate is diluted with water to the desired concentration.
To test for protective activity, young plants are sprayed with the preparation of active compound at the stated application rate. After the spray coating has dried on, 2 small pieces of agar colonized by Botrytis cinerea are placed onto each leaf. The inoculated plants are placed in a darkened chamber at about 20° C. and 100% relative atmospheric humidity.
The size of the infected areas on the leaves is evaluated 2 days after the inoculation. 0% means an efficacy which corresponds to that of the control, whereas an efficacy of 100% means that no infection is observed.
The table below clearly shows that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.







TABLE H







Botrytis cinerea test (bean)/protective










Application rate of




active compound
Efficacy in %










Active compounds
in g/ha
found*
calc.**













(1-1)
5
54



(9-3) pyrimethanil
5
4


(12-4) iprodione
5
13


(1-1) + (9-3) pyrimethanil (1:1)
5 + 5
92
56


(1-1) + (12-4) iprodione (1:1)
5 + 5
100
60





*found = activity found


**calc. = activity calculated using Colby's formula






Example I
Alternaria mali Test (In Vitro)/Microtitre Plates
The microtest is carried out in microtitre plates using potato dextrose broth (PDB) as liquid test medium. The active compounds are used as technical grade a.i., dissolved in acetone.
For inoculation, a spore suspension of Alternaria mali is used. After 5 days of incubation in the dark and with shaking (10 Hz), for each filled cavity of the microtitre plates, the light transmittance is determined with the aid of a spectrophotometer.
0% means an efficacy which corresponds to the growth in the controls, whereas an efficacy of 100% means that no fungal growth is observed.
The table below clearly shows that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.







TABLE I







Alternaria mali test (in vitro)/microtitre plates










Application rate of




active compound
Efficacy in %










Active compounds
in ppm
found*
calc.**













(1-1)
0.03 
51




0.003
25


(10-3) carbendazim
0.03 
15


(19-3) fenamidone
0.003
2


(20-1) pencycuron
0.003
11


(1-1) + (10-3) carbendazim (1:1)
0.03 + 0.03
79
59


(1-1) + (19-3) fenamidone (1:1)
0.003 + 0.003
35
27


(1-1) + (20-1) pencycuron (1:1)
0.003 + 0.003
67
33





*found = activity found


**calc. = activity calculated using Colby's formula






Example J
Rhizoctonia solani Test (In Vitro)/Microtitre Plates
The microtest is carried out in microtitre plates using potato dextrose broth (PDB) as liquid test medium. The active compounds are used as technical grade a.i., dissolved in acetone.
For inoculation, a mycelium suspension of Rhizoctonia solani is used. After 5 days of incubation in the dark and with shaking (10 Hz), for each filled cavity of the microtitre plates, the light transmittance is determined with the aid of a spectrophotometer.
0% means an efficacy which corresponds to the growth in the controls, whereas an efficacy of 100% means that no fungal growth is observed.
The table below clearly shows that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.







TABLE J







Rhizoctonia solani test (in vitro)/microtitre plates










Application




rate of



active compound
Efficacy in %










Active compounds
in ppm
found*
calc.**





(1-1)
0.3
80




0.1
40


(17-1) fosetyl-A1
0.3
24


(11-2) propamocarb
0.1
25


(1-1) + (17-1) fosetyl-A1 (1:1)
0.3 + 0.3
98
85


(1-1) + (11-2) propamocarb (1:1)
0.1 + 0.1
88
55





*found = activity found


**calc. = activity calculated using Colby's formula






Example K
Septoria tritici Test (In Vitro)/Microtitre Plates
The microtest is carried out in microtitre plates using potato dextrose broth (PDB) as liquid test medium. The active compounds are used as technical grade a.i., dissolved in acetone.
For inoculation, a spore suspension of Septoria tritici is used. After 7 days of incubation in the dark and with shaking (10 Hz), for each filled cavity of the microtitre plates, the light transmittance is determined with the aid of a spectrophotometer.
0% means an efficacy which corresponds to the growth in the controls, whereas an efficacy of 100% means that no fungal growth is observed.
The table below clearly shows that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.







TABLE K







Septoria tritici test (in vitro)/microtitre plates










Application rate of




active compound
Efficacy in %










Active compounds
in ppm
found*
calc.**





(1-1)
0.01
15



(14-3) triazoxide
0.01
29


(1-1) + (14-3) triazoxide (1:1)
0.01 + 0.01
69
40





*found = activity found


**calc. = activity calculated using Colby's formula






Example L
Sphaerotheca fuliginea Test (Gherkin)/Protective
To produce a suitable preparation of active compound, the substance to be tested is homogenized in a mixture of acetone/Tween/water. The suspension is then diluted with water to the desired concentration.
Gherkin plants (Vert petit de Paris cultivar) are sown in starter cups on 50/50 peat soil/pozzolana soil substrate and cultivated at 20° C./23° C. At the 2-leaf stage, the plants are sprayed with the preparation of active compound at the stated application rate.
To test for protective activity, the plants are, after 24 h, sprayed with an aqueous spore suspension of Sphaerotheca fuliginea (100 000 spores/ml). The plants then remain at 20° C./25° C. and 60/70% relative atmospheric humidity.
Evaluation is carried out 21 days after the inoculation. 0% means an efficacy which corresponds to that of the control, whereas an efficacy of 100% means that no infection is observed.
The table below shows clearly that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.







TABLE L







Sphaerotheca fuliginea test (gherkin)/protective










Application rate of
Efficacy in %










Active compounds
active compound in ppm
found*
calc.**





(1-1)
8
60



(6-2) boscalid
8
50


(1-1) + (6-2) boscalid (1:1)
8 + 8
98
80





*found = activity found


**calc. = activity calculated using Colby's formula

## Claims

1. A composition comprising the carboxamide (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide and at least one triazole selected from the group consisting of
(3-3) propiconazole,
(3-12) epoxiconazole,
(3-17) tebuconazole, and
(3-21) bitertanol,
in a ratio of 20:1 to 1:20 of carboxamide to triazole.

2. A composition according to claim 1, wherein the carboxamide and triazole are present in a synergistic ratio.

3. A composition according to claim 1, wherein the carboxamide and triazole are present in a 1:1 ratio.

4. A composition comprising the carboxamide (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide and (3-15) prothioconazole in a ratio of 10:1 to 1:20 of carboxamide (1-1) to (3-15) prothioconazole.

5. The composition according to claim 4, wherein the carboxamide (1-1) and (3-15) prothioconazole are present in a synergistic ratio.

6. The composition according to claim 4, wherein the carboxamide (1-1) and (3-15) prothioconazole are present in a 1:1 ratio.

7. A method for controlling unwanted phytopathogenic fungi, comprising applying the composition according to claim 1 to the unwanted phytopathogenic fungi and/or their habitat.

8. A process for preparing fungicidal compositions, comprising mixing the composition according to claim 1 with extenders and/or surfactants.

9. A method for controlling unwanted phytopathogenic fungi, comprising applying the composition according to claim 4 to the unwanted phytopathogenic fungi and/or their habitat.

10. A process for preparing fungicidal compositions, comprising mixing the composition according to claim 4 with extenders and/or surfactants.